Aclaris Therapeutics, Inc.  
Protocol Number: ATI-[ZIP_CODE]-AAB-201 
CONFIDENTIAL 
Page 1 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                     CLINICAL STUDY PROTOCOL 
 
Protocol Number: ATI-[ZIP_CODE]-AAB-[ADDRESS_1042042].  
Suite 200 
Wayne, PA [ZIP_CODE] 
Telephone: ([PHONE_3558] 
Facsimile: ([PHONE_3559] 
 
Study Contact 
[CONTACT_760950], RN, MSN 
Sr. Director, Clinical Development 
Aclaris Therapeutics, Inc. 
[ADDRESS_1042043].  
Suite 200 
Wayne, PA [ZIP_CODE] 
Telephone: ([PHONE_15878] 
Mobile: ([PHONE_15879] 
E-mail: [EMAIL_2357] 
 
Medical Monitor 
Terrence Chew, MD RAC 
Aclaris Therapeutics, Inc. 
[ADDRESS_1042044].  
Suite 200 
Wayne, PA [ZIP_CODE] 
Telephone: ([PHONE_15880] 
E-mail: [EMAIL_2358] 
 
Safety Monitor: 
ProPharma 
E-mail: [EMAIL_2427] 
Serious Adverse Event Facsimile: ([PHONE_15881]  
 
This document is a privileged and confidential communication of Aclaris Therapeutics, Inc. Acceptance of this document 
constitutes an agreement by [CONTACT_1955][INVESTIGATOR_118141], published or disclosed 
without prior written approval from Aclaris Therapeutics, Inc.  
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 3 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                      
INVESTIGATOR SIGNATURE [CONTACT_355340]:  ATI-[ZIP_CODE]-AAB-201 
 
Protocol Title:  An Open-label Pi[INVESTIGATOR_635345], Tolerability and Efficacy of ATI-[ZIP_CODE] Topi[INVESTIGATOR_760919]-Daily in Adult Subjects with Eyebrow Loss due to Alopecia Areata, 
Alopecia Universalis or Alopecia Totalis  
 
Protocol Version: 1.[ADDRESS_1042045] the trial in accordance with the principles of ICH Good 
Clinical Practice and the Declaration of Helsinki. 
 
I will maintain as confidential all written and verbal information provided to me by [CONTACT_1034], 
including but not limited to, the protocol, case report forms, investigator’s brochure, material supplied at 
investigator meetings, minutes of teleconferences, etc. Such material will only be provided as necessary 
to site personnel involved in the conduct of the trial, involved Institutional Review Board (IRB), Ethics 
Committees, or local regulatory authorities. 
 
I will obtain written informed consent from each prospective trial subject or each prospective trial 
subject’s legal representative prior to conducting any protocol-specified procedures. The informed 
consent document used will have the approval of the IRB appropriate for my institution. 
 
I will maintain adequate source documents and record all observations, treatments, and procedures 
pertinent to trial subjects in their medical records. I will accurately complete the case report forms 
supplied by [CONTACT_21411] a timely manner. I will ensure that my facilities and records will be available 
for inspection by [CONTACT_18485], the IRB, and/or local regulatory authorities. I will ensure 
that I and my staff are available to meet with Sponsor representatives during regularly scheduled 
monitoring visits. 
 
I will notify the Sponsor within 24 hours of any serious adverse events. Following this notification, a 
written report describing the serious adverse event will be provided to the Sponsor as soon as possible, 
but no later than five days following the initial notification. 
 
 
_________________________________________________________ 
Investigator Name (Print) 
 
 
_________________________________________________________         _______________________ 
Investigator Signature                                                                                        [CONTACT_760960]: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 4 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                     Table of Contents 
1. SYNOPSIS  ..................................................................................................................................................... [ADDRESS_1042046] Identifier (SI)  ............................................................................................................................. 23  
5.8. Replacement Subjects  ............................................................................................................................. 23  
6. INVESTIGATIONAL PLAN  .................................................................................................................. 23  
6.1. Study Design  ............................................................................................................................................. 23  
6.2. Study Flow Chart  .................................................................................................................................... 24  
6.3. Study Visits Description and Procedures  .......................................................................................... 25  
6.3.1. Visit 1/ Screening (Week -4 to 0)  ....................................................................................................... 25  
6.3.2. Visit 2/ Baseline (Day 1)  ...................................................................................................................... 26  
6.3.3. Visits 3-9 (Weeks 1, 2, 4, 8, 12, 16 and 20)  ...................................................................................... 27  
6.3.4. Visit 10 (Week 24)  ................................................................................................................................. 28  
6.3.5. Visit 11 (Week 28)  ................................................................................................................................. [ADDRESS_1042047] Instructions  ................................................................................................................................ 29  
6.5. STUDY DURATION  .............................................................................................................................. 29  
6.6. STUDY MEDICATIONS  ...................................................................................................................... 30  
6.6.1. Study medication identity  ................................................................................................................... 30  
6.6.2. Study medication packaging and labeling  ...................................................................................... 31  
6.6.3. Method of treatment assignment  ...................................................................................................... 31  
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 5 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                     6.6.4. Subject Eligibility to Receive Study Medication  ........................................................................... [ADDRESS_1042048]  ...................................................................................................................... 32  
6.6.8. Dose modification  ................................................................................................................................. 32  
6.7. Study Medication Management  ........................................................................................................... 33  
6.7.1. Accountability  ....................................................................................................................................... 33  
6.7.2. Return and disposition of study supplies  ........................................................................................ 33  
6.8. Other Study Supplies  .............................................................................................................................. 33  
6.9. Blinding ...................................................................................................................................................... 33  
6.9.1. Verification of blinding  ....................................................................................................................... 33  
6.9.2. Unblinding the study medication  ...................................................................................................... 33  
7. STUDY ASSESSMENTS  ......................................................................................................................... 33  
7.1. Effectiveness Evaluations  ...................................................................................................................... 34  
7.1.1. Clinician’s Eyebrow Assessment (CEA)  ......................................................................................... [ADDRESS_1042049]’s Eyebrow Assessment (SEA)  ............................................................................................. [ADDRESS_1042050] Eyebrow Satisfaction (SES)  ................................................................................................ 36  
7.2. Safety Evaluations  ................................................................................................................................... 36  
7.2.1. ECGs ........................................................................................................................................................ 36  
7.2.2. Brief physical examination  ................................................................................................................. 37  
7.2.3. Vital signs  ............................................................................................................................................... 37  
7.2.4. Clinical laboratory sampling  ............................................................................................................. 38  
7.2.5. Local Tolerability Assessment (LTA)  .............................................................................................. 39  
7.2.6. Urine Pregnancy tests  .......................................................................................................................... 41  
7.3. Other Evaluations  ................................................................................................................................... 41  
7.3.1. Demographics, medical history and alopecia areata history  ..................................................... 41  
7.3.2. Standardized photography  ................................................................................................................. 42  
8. ADVERSE EVENTS  ................................................................................................................................. 42  
8.1. Definitions  ................................................................................................................................................. 42  
8.1.1. Adverse events (AE)  ............................................................................................................................. 42  
8.1.2. Serious adverse event (SAE)  .............................................................................................................. 43  
8.1.3. Adverse event reporting period  ......................................................................................................... 43  
8.1.4. Severity .................................................................................................................................................... 44  
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 6 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                     8.1.5. Relationship to study medication  ...................................................................................................... 44  
8.2. Reporting Procedures  ............................................................................................................................. 44  
8.2.1. Procedures for reporting adverse events  ........................................................................................ 44  
8.2.2. Procedure for reporting a serious adverse event  .......................................................................... 45  
8.2.3. Safety Monitoring ECG Discontinuation Criteria  ....................................................................... 45  
8.2.4. Study Medication Interruption and Discontinuation  .................................................................. 46  
[IP_ADDRESS] Study Medication Interruption .................................................................................................................. 46  
[IP_ADDRESS] Study Medication Discontinuation  ........................................................................................................... 47  
9. PREGNANCY  ............................................................................................................................................. 47  
9.1. Definition of Women of Child Bearing Potential (WOCBP)  ........................................................ [ADDRESS_1042051] (IRB)/Ethics Committee (EC)  ........................................................... [ADDRESS_1042052] and Protocol Amendments  ....................................................................................... 52  
12.5. Regulatory Documents  ........................................................................................................................... 52  
12.6. Contractual Requirements  .................................................................................................................... 52  
12.7. Data Collection and Archiving  ............................................................................................................. 53  
12.7.1. Data collection  ....................................................................................................................................... 53  
12.7.2. Source documentation  ......................................................................................................................... 53  
12.7.3. Archiving  ................................................................................................................................................ 53  
13. References  .................................................................................................................................................... 54  
14. APPENDIX A:  PARTICIPANT INSTRUCTION SHEET  ............................................................ 56  
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 7 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                      
1. SYNOPSIS 
Protocol Number:                  ATI-[ZIP_CODE]-AAB-201 
Protocol Title: An Open-Label Pi[INVESTIGATOR_635345], Tolerability and 
Efficacy of ATI-[ZIP_CODE] Topi[INVESTIGATOR_118149]-
Daily in Adult Subjects with Eyebrow Loss due to Alopecia 
Areata, Alopecia Universalis or Alopecia Totalis 
Sponsor:  
Phase of Development: Aclaris Therapeutics, Inc. 
Phase 2 
Study Drug Description: 
ATI-[ZIP_CODE] Topi[INVESTIGATOR_28198] 0.46% 
 
Study Objective: 
The main objective of this study is to assess the safety, tolerability and efficacy of ATI-[ZIP_CODE] 
Topi[INVESTIGATOR_28198] 0.46% in subjects with unilateral or bilateral loss of eyebrow hair due to 
alopecia areata (AA), alopecia universalis (AU) or alopecia totalis (AT).  
 
Study Design: 
This is an open-label study which will be conducted at [ADDRESS_1042053] 6 months, but 
not more than seven years. A total of approximately 12 subjects will apply ATI-[ZIP_CODE] Topi[INVESTIGATOR_118151] 0.46%, to the affected eyebrow(s) twice-daily (BID) for 24 weeks. 
 
After completing Visit 1 (start of the screening period), subjects will be assessed for eligibility 
to receive study medication.   
 
Subjects will apply study medication to the entire affected eyebrow(s), twice-daily for 24 
weeks. The 24-week treatment period will be followed by a 4-week no-treatment follow-up 
period. Assessment of response to treatment will be performed at Week 4, Week 8, Week 12, 
Week 16, Week 20, Week 24 and Week 28.   
 
Safety and tolerability will be evaluated throughout the study by [CONTACT_760951]-
cardiograms (ECG), clinical laboratory tests, adverse events and vital signs. 
 
The duration of the study participation is anticipated to be a maximum of 233 days (an up to 28-
day screening period, a 169-day treatment period with a 4-day window, a 28-day no-treatment 
follow-up period with a window of 4 days). 
 
Study visits are: 
 Visit 1 (Day -28 to 0): screening; start eligibility assessment period 
 Visit 2 (Week 0): initiation of twice -daily study medication application  
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 8 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                      Visits 3-10 (Weeks 1-24): treatment period 
 Visit 11 (Week 28): no-treatment period follow-up; end of study 
Number of Subjects to be Enrolled: 
Approximately 12 subjects will be enrolled in this study.  
Number of Study Sites: 
This study will be conducted at up to 2 sites in the US.  
Inclusion Criteria: 
To be eligible for the study, subjects must fulfill all the following criteria:  
1. Subject is at least [ADDRESS_1042054] history and clinical examination, a clinical diagnosis of 
AA, AU or AT with no eyebrow hair in the affected area(s) and no eyebrow regrowth 
over the previous 6 months.  Affected area is defined as the area(s) of eyebrow hair 
loss identified at Baseline. 
3. Subject has a Clinician Eyebrow Assessment score of 0 (No eyebrow hair in the 
affected area) for at least one eyebrow.   
4. Subject has a Subject Eyebrow Assessment score of 0 (No eyebrow hair in the affected 
area) for at least one eyebrow.   
5. Subject has a duration of the current epi[INVESTIGATOR_457974], AU or AT with unilateral or 
bilateral loss of eyebrow hairs (with at least one distinct patch of >30% loss of 
eyebrow hair) for at least 6 months and no more than seven years prior to Visit 1.  
6. Subjects who are Women of Childbearing Potential (WOCBP) must have a negative 
serum pregnancy test at Screening and a negative urine pregnancy test at Baseline and 
agree to use a highly effective method of birth control for the duration of the study and 
for [ADDRESS_1042055] agrees to refrain from any eyebrow removal ( e.g.¸ plucking, threading, etc.) for 
the duration of the study . 
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 9 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                     13. Subject agrees to refrain from any cosmetic surgery ( e.g., pi[INVESTIGATOR_77219], tattooing, etc.), on 
the treatment areas, for the duration of the study. 
14. Subject can comprehend and is willing to sign an Informed Consent Form (ICF). 
15. Sexually active male subjects must agree to use a barrier method of contraception from 
the first application of study medication to at least [ADDRESS_1042056] application of 
study medication. 
  
Exclusion Criteria: 
Any subject who meets one or more of the following criteria will not be included in this study:  
1) Subject has, in the opi[INVESTIGATOR_871], permanent eyebrow loss attributed to causes 
other than AA, AU or AT such as overgrooming, or scarring hair loss. 
2) Subject currently has, or has a history of, skin disease in the eyebrow area ( e.g., psoriasis, 
seborrheic dermatitis, etc.) that, in the opi[INVESTIGATOR_871], would interfere with the 
study medication application or study assessments. 
3) Subject currently has, or has a history of, severe, progressive or uncontrolled autoimmune, 
metabolic, endocrinologic, renal, hepatic, gastrointestinal, pulmonary, cardiovascular, 
genitourinary ( i.e., renal disease), hematological disease, neurologic or cerebral disorders, 
infectious disease or coagulation disorders that, in the opi[INVESTIGATOR_871], put the 
subject at undue risk by [CONTACT_28224]. 
4) Subject currently has, or has a history of, proven or suspected systemic or cutaneous 
malignancy and /or lymphoproliferative disease, other than a history of adequately treated, 
well healed and completely cleared non-melanoma skin cancers ( e.g. basal or squamous 
cell carcinoma) treated successfully at least one year prior to Visit 1.   
5) Subject currently has evidence of active or latent bacterial infection, including tuberculosis, 
or viral infections at the time of enrollment or a history of incompletely treated or untreated 
tuberculosis.  Subjects who have completed therapy for latent tuberculosis may participate.   
6) Subject has a history of serious local infection ( e.g., cellulitis, abscess) or a systemic 
infection, including but not limited to, pneumonia or septicemia, within [ADDRESS_1042057] complete the 
antibiotic course prior to enrollment in the study.  
7) Subjects positive for HIV, Hepatitis B or C.  Subjects with serologic evidence of Hepatitis 
B vaccination (HepB surface Ab without the presence of HepB surface Ag) will be allowed 
to participate. 
8) Subject currently has or has a known history of herpes zoster or cytomegalovirus (CMV) 
within 8 weeks prior to Visit 1.    
9) Subject has a history of frequent outbreaks of Herpes Simplex Virus defined as 4 or more 
epi[INVESTIGATOR_11114]. 
10) Subject has any history of eyebrow tattooing, or microblading that in the opi[INVESTIGATOR_760920]. 
11) Subject has used any semi-permanent eyebrow coloring ( e.g., tinting, dying, etc.) within 6 
months prior to Visit 1 that in the opi[INVESTIGATOR_760921] o f safety or efficacy . 
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 10 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                     12) Clinically significant laboratory abnormalities at Screening that, in the opi[INVESTIGATOR_684], would make the subject a poor candidate for the study.   
13) Subjects with absolute neutrophil count <1,000/mm3, or platelet count <50,000/ml. 
14) Subject used any of the following therapi[INVESTIGATOR_160764] 1: 
Systemic therapi[INVESTIGATOR_014]: 
 Disease Modifying Anti-Rheumatic Drugs (DMARDS), Biologics or 
immunosuppressants, such as: anakinra, adalimumab, azathioprine, 
glucocorticosteroids, cyclosporine, etanercept, infliximab, methotrexate, TNF 
inhibitors, ustekinumab, secukinumab, ixekizumab, certolizumab pegol: 4 
weeks or 5 half-lives whichever is longer 
 Oral retinoids: 12 weeks 
 Plaquenil: 8 weeks 
 JAK inhibitors (oral or topi[INVESTIGATOR_2855]): 1 year 
 Intralesional steroids on the eyebrow area: 4 weeks 
Topi[INVESTIGATOR_760922]: 
 Phototherapy, Laser Therapy: 12 weeks 
 Anthralin, bimatoprost, glucocorticosteroids, diphencyprone, diphenylcycloprophenone 
(DPCP), Squaric acid dibutyl ester (SADBE), minoxidil, pi[INVESTIGATOR_031], tacrolimus: 4 
weeks 
 Topi[INVESTIGATOR_12969] (prescription and over-the-counter) that contain retinoids, retinol, 
alpha hydroxy acids (e.g. glycolic, lactic acids) and beta hydroxy acids (e.g. salicylic 
acid) on and around the eyebrow area: 4 weeks 
15) Subject has a history of sensitivity to any of the ingredients in the study medication. 
16) Subject has participated in an investigational drug or device trial in which administration of 
an investigational study drug or device occurred within 30 days or 5 half-lives (whichever 
is longer) prior to Visit 1.  Subjects who have participated in a study of an investigational 
drug, device or biologic agent for alopecia areata (AA, AU or AT) within 1 year of screening 
will be eligible to participate only with individual permission from the Medical Monitor. 
17) History of or current alcohol or drug abuse within 2 years of assessment for study enrollment. 
18) Screening ECG findings of: 
 QTcF >450msec for males or >470msec for females (use of the ECG algorithm is 
acceptable for this purpose) 
 Heart rate < 45 or > 100 beats/minutes (inclusive) 
 Rhythm disturbance other than sinus arrhythmia or ectopic supraventricular rhythm 
(ectopic atrial rhythm) 
 Conduction disturbance including PR >240msec, pre-excitation (delta wave and PR 
<120msec), second degree or higher AV block 
 Acute or chronic signs of ischemia  
 Left Bundle Branch Block 
 Prior myocardial infarction 
 
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 11 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                     Criteria for Evaluation: 
Efficacy: 
The investigator will evaluate the severity of eyebrow loss using the Clinician’s Eyebrow 
Assessment. Subjects will evaluate the severity of eyebrow loss using the Subject’s Eyebrow 
Assessment. 
 
Safety: 
The investigator will assess clinical laboratory safety tests, vital sign readings, concomitant 
therapi[INVESTIGATOR_014], urine pregnancy test results, and adverse event (AE) information throughout the study. 
 
Other: 
Subjects will assess their satisfaction with the status of each eyebrow using the Subject Eyebrow 
Satisfaction scale. Standardized color photographs to assist with documenting the status of the 
subject’s eyebrows will be taken throughout the study.  
Study Drug Administration: 
Subjects will apply ATI-[ZIP_CODE] Topi[INVESTIGATOR_28198] 0.46% BID for 24 weeks to the affected 
eyebrow(s).  At Visit 2 (Baseline), after confirmation of the inclusion and exclusion criteria, an 
investigational staff member will instruct the subject on the proper study medication application 
technique, observe the first study medication application and monitor the subject for at least [ADDRESS_1042058] will then start a 2 4-week treatment period.  
 
Statistical Methods: 
Summary descriptive statistics (N, mean, median, SD) by [CONTACT_760952].  Primary and secondary efficacy parameters are described below: 
 
Mean change from baseline in eyebrow growth will be calculated as the mean change in the 
Clinician’s Eyebrow Assessment (CEA) from Visit 2 (Baseline) compared to end of treatment 
(Visit 10). The CEA evaluates eyebrows on a scale from “No eyebrow hair” (grade 0) to “Full 
eyebrow hair” (grade 4).     
 
Mean change from baseline in the Subject’s Eyebrow Assessment (SEA) will be calculated from 
Visit 2 (Baseline) to end of treatment (Visit 10). 
 
Mean change from baseline in the Subject’s Eyebrow Satisfaction (SES) will be calculated from 
Visit 2 (Baseline) to end of treatment (Visit 10). 
 
All efficacy summaries will be based on the per-protocol population including all subjects who 
have Baseline (Visit 2) and Visit 10 efficacy data and no major protocol violations. 
 
Safety analyses will include descriptive statistics calculated on the safety parameters using the 
safety population. The proportion of subjects with treatment-emergent adverse events will be 
tabulated and presented by [CONTACT_10607] (MedDRA) System 
Organ Class. Vital signs and clinically significant  abnormal laboratory results will also be 
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 12 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                     tabulated and presented. Change from Baseline in the Local Tolerability Assessments (LTA) 
to end of treatment (Visit 10) will be summarized.  
 
Data from all enrolled and treated subjects will be presented and summarized. Safety summaries 
will include listings of adverse events incidences within each MedDRA System Organ Class, 
and changes from pre-application values in vital signs. Adverse event summaries will be 
presented by [CONTACT_458011], 
both overall and by [CONTACT_7204].  
  
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 13 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                     2. LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
Abbreviation Term 
AA Alopecia Ar eata 
AE  Adverse Event  
ALT Alanine aminotransferase  
ANCOVA  Analysis of Covariance  
ANOVA Analysis of Variance  
AST Aspartate aminotransferase  
AT Alopecia Totalis  
AU Alopecia Universalis  
BID Twice-daily 
BUN Blood Urea Nitrogen  
°C Degrees Centigrade  
CD Cluster of Differentiation  
CEA Clinician’s Eyebrow Assessment  
CMV Cytomegalovirus  
CRA Clinical Research Associate  
CRF Case Report Form  
CS Clinically Significant  
DMARDS  Disease modifying anti -rheumatic drugs  
DPCP Diphenylcycloprophenone  
e.g.  for example (Latin; exempla gratia)  
EC Ethics Committee  
ECG Electrocardiogram  
eCRF Electronic Case Report Form  
EHL Eyebrow Hair Loss  
°F Degrees Fahrenheit  
FDA Food and Drug Administration  
G Gram 
GCP Good Clinical Practice  
HEENT Head, Eye, Ear, Nose and Throat  
HIPAA Health Insurance Portability and Accountability Act of 1996  
HIV Human Immunodeficiency Virus  
IB Investigator’s Brochure  
ICF Informed Consent Form  
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 14 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                     Abbreviation Term 
ICH International Conference on Harmonization  
i.e.  that is (Latin; id est)  
IFN Interferon 
IL Interleukin  
IRB Institutional Review Board  
IUD Intrauterine Device  
IUS Intrauterine Hormone Releasing System  
JAK Janus Kinase  
LDH Lactate Dehydrogenase  
LTA Local Tolerability Assessment  
LOCF Last Observation Carried Forward  
MedDRA  Medical Dictionary for Regulatory Activities  
MHC Major Histocompatibility Complex  
ml Milliliter 
Mm Millimeter  
NCS Not Clinically Significant  
NK/ NKG  Natural Killer/ Natural Killer Group  
OTC Over-The-Counter 
PDT Photodynamic Therapy  
PUVA Psoralen and Ultraviolet A  
SADBE Squaric acid dibutyl ester  
SAE Serious Adverse Event  
SEA Subject’s Eyebrow Assessment  
SES Subject’s Eyebrow Satisfaction  
SI Subject Identifier  
SOP Standard Operation Procedure  
STAT Signal Transducer and Activator of Transcription  
TEAE Treatment Emergent Adverse Event  
Tyk2 Tyrosine Kinase [ADDRESS_1042059]  
US [LOCATION_002]  
UVA Ultraviolet A  
UVB Ultraviolet B  
WOCBP Women of childbearing potential  
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 15 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                     3. INTRODUCTION 
Aclaris Therapeutics, Inc. is developi[INVESTIGATOR_118163]-[ZIP_CODE] Topi[INVESTIGATOR_760923].  ATI-[ZIP_CODE] is a potent, highly selective inhibitor of Janus kinase 1 (JAK 1) and Janus 
kinase 3 (JAK 3). 
 
3.1. Summary 
Overview of Alopecia Areata 
Alopecia areata (AA) is an autoimmune dermatologic condition which in its mildest form is 
typi[INVESTIGATOR_118165]-scarring hair loss on the scalp and/or body. More severe 
forms of AA include total scalp hair loss, known as alopecia totalis (AT), and total loss of all the 
hair on the scalp and body, importantly, including loss of eyebrows, eyelashes, and intranasal hair- 
known as alopecia universalis (AU). While spontaneous regrowth of hair is common in the milder 
form of AA (patchy), where the hair loss may wax and wane, in patients with the extensive hair 
loss of AT or AU, spontaneous hair regrowth is rare. AA affects both males and females across all 
ethnic groups and is the most prevalent autoimmune disease in the [LOCATION_002], with a lifetime 
risk of 1.7% (Safavi 1995). About two-thirds of affected individuals are 30 years old or younger 
at the time of disease onset.  
 
The course of AA is unpredictable and while up to 50% of patients may recover within [ADDRESS_1042060] more than one epi[INVESTIGATOR_118166] (Price 2008). Factors 
portending a poorer prognosis for regrowth are: more extensive hair loss presentations (extensive 
AA, AT, AU), an ophiasis pattern of hair loss, a long duration of hair loss, a positive family history, 
the presence of other autoimmune diseases, nail involvement, and young age of first onset (Tosti 
2006, Weise 1996). In children, the disease may have a tendency towards worsening with time, 
even if the initial presentation was mild and the progressively disfiguring nature of the disease can 
be psychologically devastating. AA is highly associated with numerous psychiatric comorbidities 
including adjustment disorders, anxiety disorders and depression in both children and adults, and 
an effective treatment for AT and AU, the more severe forms of the disease, represents a significant 
unmet medical need (Bilgic 2014, Ruiz-Doblado 2003, Alkhalifah 2010).  
 
The clinical development of innovative therapi[INVESTIGATOR_118167]-based treatments for AA. A Cochrane database 
review highlighted that few therapi[INVESTIGATOR_118168]-based assessment (Delamere, 2008). This lack of good evidence-based data 
remains a challenge for physicians attempting to select efficacious treatments for their patients 
and, as a result, numerous approaches to treatment exist and are typi[INVESTIGATOR_760924], the extent and/or duration of the disease, patient expectations, cost 
considerations (both time and financial resources) and physician preferences and experience. 
 
Common treatments for the less severe (patchy) form of AA include corticosteroids, either 
topi[INVESTIGATOR_457955], or the induction of an allergic 
reaction at the site of hair loss using a topi[INVESTIGATOR_118171] - an approach known as 
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 16 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                     topi[INVESTIGATOR_118210], typi[INVESTIGATOR_760925] 
(DPCP), squaric acid dibutyl ester (SADBE), or treatment with topi[INVESTIGATOR_118174]. While these same 
treatment options may be utilized for the more severe forms of AA, their use in the more severe 
forms of AA is limited not only due to limited efficacy, but also because of the impracticality of 
using them over extensive body surface areas. Additional treatments used for extensive forms of 
AA (AT, AU), have included systemic steroids (pulsed or chronically administered), 
immunosuppressive agents such as cyclosporine or methotrexate, phototherapy with psoralen 
+UVA (PUVA), narrow-band UVB, photodynamic therapy (PDT), laser therapy ( e.g., excimer 
laser, fractional photothermolysis lasers), prostaglandin analogs, etanercept, bexarotene and 
others, all with varying degrees of success and each with its inherent risk of adverse effects and 
unproven efficacy (Alkhalifah 2010, Price 1999, Hordinsky 2015, Strober 2005). Most recently, 
however, a breakthrough in the understanding of the pathophysiology of AA and several case 
reports in the literature have suggested that a group of inhibitors of the JAK-STAT pathway, the 
Janus Kinase (JAK) inhibitors, or “jakinibs” may be efficacious in the treatment of AA even in its 
most severe phenotypes, AT and AU (Jabbari, 2015, Pi[INVESTIGATOR_77332], 2015, Xing 2014).  
 
The JAKs, are members of a family of tyrosine kinases that are involved in cytokine receptor 
signaling. The JAK family of enzymes (JAK1, JAK2, JAK3, Tyk2) plays an essential role in 
regulating the signaling process of most cytokines in cells by [CONTACT_760953], or STATs, within the cells. Once these JAK receptors are activated by [CONTACT_118220] a cytokine to the appropriate receptor, they initiate a JAK-STAT signaling pathway which can 
modify gene expression and modulate important regulatory functions in the cell, including 
regulating immune and inflammatory responses. JAK1 and JAK3 are constitutively associated 
with the alpha chain and the common gamma chain (γc), respectively, of the receptors for 
interleukin-2 (IL2), interleukin-4 (IL-4), interleukin-7 (IL-7) interleukin-9 (IL-9), interleukin-15 
(IL-15), and interleukin-21 (IL-21). When these cytokines bind to their respective receptors, JAK1 
and JAK3 are activated and initiate a signaling cascade that drives key inflammatory events, 
including lymphocyte activation and proliferation. The JAK inhibitors can block the cytokine 
receptor signaling pathways, (in this instance JAK1 and JAK3) blocking JAK-STAT transcription 
activation, and can therefore modulate inflammatory or immune responses, which can be 
beneficial in a variety of disease states, particularly, as recently reported, AA (Xing 2014). In that 
report, pharmacologic inhibition of JAK kinase signaling (JAK-STAT signaling) was reported to 
promote hair growth in both genetic mouse models of alopecia and in human subjects. 
 
Immunopathology & Pathophysiology of AA 
AA results from an autoimmune attack on the hair follicles that results in growing anagen-phase 
terminal hairs being induced to prematurely enter the telogen-phase and then shed. In its most 
acute state, AA demonstrates a histopathologically characteristic white cell infiltrate, the so called 
“swarm of bees”, encircling the human hair follicle, though more chronic forms typi[INVESTIGATOR_760926] a more sparse infiltrate (Jabbari 2016, Whiting 2003). Though the exact autoantigens 
expressed in the perifollicular epi[INVESTIGATOR_118176] T-cells to infiltrate the normally 
immunologically privileged hair follicle have been unknown, the T-cells that home to the hair 
follicle have been demonstrated to consist of both CD4 and CD8 cells. Most recent studies have 
further characterized a specific subpopulation of activated NKG2D-bearing CD8 T cells as being 
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 17 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                     prominent in the peribulbar infiltrate, and it is now currently felt that these CD8+NKG2D+ effector 
T cells preferentially localize to dermal sheath cells aberrantly expressing high levels of MHC 
molecules and NKG2D ligands. Interferons, as key activators of the MHC locus and of the cellular 
immune response, appear to play a key role in eliminating the immunologic privilege of the hair 
follicle and in inducing and maintaining the pathologic inflammatory response in AA. This is also 
seen in the C3H-HeJ mouse model of AA, in which IFN-γ is required for pathogenesis, and in 
which administration of IFN-γ accelerates disease (Gilhar 2005, Hirota 2003). 
 
AA has been viewed as a Th1-driven disease and, consistent with a pathogenic cellular immune 
response, elevated Th1 cytokines/ chemokines (IFN-induced chemokines [IP-10/CXCL10]) are 
seen in the peripheral blood of AA patients and IFN-inducible gene signatures have been described 
in the skin of AA patients and may correlate with disease activity (Arca 2004, Barahmani 2009, 
Kuwano 2007). Additionally, transcriptional profiles in human AA patients have shown a Type I 
IFN response in lesional biopsies and Th1 skewing and elevated IFN response 
cytokines/chemokines in both the peripheral blood and in reviewed scalp biopsies (Jabbari 2015, 
Xing 2014, Jabbari 2016). The cellular source of IFN-γ is hypothesized to be the T cells as in the 
AA mouse model IFN-gamma producing CD8+NKG2D+ cells dominate the dermal hair follicle 
infiltrate, and in human AA, IFN-γ producing cells were identified in 4 of 5 dermal crawl-out 
assays (Christiano 2016). Additionally, data implicate IL-15 in driving activation of IFN-
producing CD8 T cells (Xing 2014).  
 
Thus, preclinical and preliminary clinical information, as discussed above, strongly suggests that 
the primary pathophysiologic mechanism in AA (including AT and AU) is a cytokine mediated 
(primarily through T-lymphocyte induced upregulation of IL-15 and IFN gamma) induction of and 
prolonged maintenance of the telogen stage of the hair cycle. Inhibitors of the JAK/STAT pathway, 
particularly JAK1 and JAK3, are known to downregulate the effects of both IFN-gamma (through 
the inhibition at JAK1), and IL-15 (through inhibition at both JAK1 and JAK 3), and several 
published case reports have demonstrated the potential for compounds that are JAK1/3 inhibitors 
to induce hair growth in patients with AA (Kim 2017, Craiglow, 2014, Gupta 2016, Scheinberg 
2016). As ATI-[ADDRESS_1042061] satisfactory 
outcomes with current therapi[INVESTIGATOR_014]. Aclaris Therapeutics, Inc. is developi[INVESTIGATOR_118163]-[ZIP_CODE] as a topi[INVESTIGATOR_118177]. Aclaris is also developi[INVESTIGATOR_118163]-[ZIP_CODE] for the treatment of AU and AT. 
ATI-[ZIP_CODE] is a prodrug that is rapi[INVESTIGATOR_118178]-systemically to ATI-[ZIP_CODE], a potent highly 
selective inhibitor of Janus kinase 1 (JAK1) and Janus kinase 3 (JAK3). In this study, we will be 
looking to see if topi[INVESTIGATOR_760927]1/JAK3 inhibitor, ATI-[ZIP_CODE], will result in 
regrowth of eyebrows in areas of loss due to AA, AU or AT. 
 
In a previous Phase 1 study in healthy volunteers, single ascending oral doses of ATI-[ZIP_CODE], 50 
mg to 500 mg and multiple ascending doses of up to 400 mg BID were well-tolerated. There were 
no SAEs. All treatment emergent adverse events (TEAEs) were transient and mild in intensity with 
the exception of 4 TEAEs: facial bone fracture, headache (2), and catheter site pain which were 
classified as moderate. The most frequently reported drug related TEAEs occurring in >5% 
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 18 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                     subjects were abdominal pain (10%), flatulence (7%), diarrhea (6%) and headache (6%). Three 
subjects showed mildly elevated ALT or AST concentrations that were considered not clinically 
significant. No clinically significant laboratory abnormalities were observed. There were no 
clinically significant findings from 12-lead ECGs or vital signs assessments.   
 
ATI-[ADDRESS_1042062]. Upon multiple dosing, pSTAT5 activity showed a more sustained 
inhibition during the dosing period.   
 
Non-clinical studies conducted with oral administration of ATI-[ZIP_CODE] and topi[INVESTIGATOR_760928]-[ZIP_CODE] support the topi[INVESTIGATOR_118180]-[ZIP_CODE] (ATI-[ADDRESS_1042063] 2017).   
 
3.2. Study Rationale 
Preclinical and preliminary clinical information, as discussed above, strongly suggests that the 
primary pathophysiologic mechanism in AA (including AT and AU) is a cytokine mediated 
(primarily through T-lymphocyte induced upregulation of IL-15 and IFN gamma) induction of and 
prolonged maintenance of the telogen stage of the hair cycle. Inhibitors of the JAK/STAT pathway, 
particularly JAK1 and JAK3, are known to downregulate the effects of both IFN-gamma (through 
the inhibition at JAK1), and IL-15 (through inhibition at both JAK1 and JAK 3), and several 
published case reports have demonstrated the potential for compounds that are JAK1/3 inhibitors 
to induce hair growth in patients with AA. As ATI-[ZIP_CODE] is a potent inhibitor at JAK 1 and JAK 
3, it is strongly suggested that ATI-[ZIP_CODE] may be effective in the treatment of AA.   
 
The purpose of this proof of concept study is to demonstrate the safety, tolerability and efficacy of 
ATI-[ZIP_CODE] Topi[INVESTIGATOR_28198], a topi[INVESTIGATOR_81191] (JAK 1/3) inhibitor in the treatment of 
unilateral or bilateral loss of eyebrow hair in subjects with AA, AT and AU.   
 
4. STUDY OBJECTIVES 
The main objective of this study is to assess the safety, tolerability and efficacy of ATI-[ZIP_CODE] 
Topi[INVESTIGATOR_28198] 0.46% in subjects with unilateral or bilateral loss of eyebrow hair due to AA, AU 
or AT. 
 
5. SELECTION AND DISPOSITION OF STUDY POPULATION 
5.1. Number of Subjects 
Approximately 12 subjects will be enrolled at 1 to 2 sites in the [LOCATION_002]. 
 
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 19 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                     5.2. Study Population Characteristics 
Male and female subjects, [ADDRESS_1042064] fulfill all the following criteria:  
1. Subject is at least [ADDRESS_1042065] history and clinical examination, a clinical diagnosis of 
AA, AU or AT with no eyebrow hair in the affected area(s) and no eyebrow regrowth 
over the previous 6 months.  Affected area is defined as the area(s) of eyebrow hair loss 
identified at Baseline. 
3. Subject has a Clinician Eyebrow Assessment score of 0 (No eyebrow hair in the affected 
area) for at least one eyebrow.   
4. Subject has a Subject Eyebrow Assessment score of 0 (No eyebrow hair in the affected 
area) for a least one eyebrow. 
5. Subject has a duration of the current epi[INVESTIGATOR_457974], AU or AT with unilateral or bilateral 
loss of eyebrow hairs (with at least one distinct patch of >30% loss of eyebrow hair) for 
at least 6 months and no more than seven years prior to Visit 1.  
6. Subjects who are Women of Childbearing Potential (WOCBP) must have a negative 
serum pregnancy test at Screening and a negative urine pregnancy test at Baseline and 
agree to use a highly effective method of birth control for the duration of the study and 
for [ADDRESS_1042066] agrees to refrain from any eyebrow removal ( e.g.¸ plucking, threading, etc.) for 
the duration of the study. 
13. Subject agrees to refrain from any cosmetic surgery ( e.g., pi[INVESTIGATOR_77219], tattooing, etc.), on the 
treatment areas, for the duration of the study. 
14. Subject can comprehend and is willing to sign an Informed Consent Form (ICF). 
15. Sexually active male subjects must agree to use a barrier method of contraception from 
the first application of study medication to at least [ADDRESS_1042067] application of 
study medication. 
   
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 20 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                     5.4. Exclusion Criteria  
Any subject who meets one or more of the following criteria will not be included in this study:  
1. Subject has, in the opi[INVESTIGATOR_871], permanent eyebrow loss attributed to 
causes other than AA, AU or AT such as overgrooming, or scarring hair loss. 
2. Subject currently has, or has a history of, skin disease in the eyebrow area ( e.g., psoriasis, 
seborrheic dermatitis, etc.) that, in the opi[INVESTIGATOR_871], would interfere with 
the study medication application or study assessments. 
3. Subject has, or has a history of, severe, progressive or uncontrolled autoimmune, 
metabolic, endocrinologic, renal, hepatic, gastrointestinal, pulmonary, cardiovascular, 
genitourinary ( i.e., renal disease), hematological disease, neurologic or cerebral disorders, 
infectious disease or coagulation disorders that, in the opi[INVESTIGATOR_871], would 
put the subject at undue risk by [CONTACT_28224]. 
4. Subject currently has, or has a history of, proven or suspected systemic or cutaneous 
malignancy and /or lymphoproliferative disease, other than a history of adequately 
treated, well healed and completely cleared non-melanoma skin cancers (basal or 
squamous cell carcinoma) treated successfully at least one year prior to Visit 1.   
5. Subject currently has evidence of active or latent bacterial infection, including 
tuberculosis, or viral infections at the time of enrollment or a history of incompletely 
treated or untreated tuberculosis.  Subjects who have completed therapy for latent 
tuberculosis may participate.    
6. Subject has a history of serious local infection ( e.g., cellulitis, abscess) or a systemic 
infection including but not limited to, pneumonia or septicemia, within [ADDRESS_1042068] complete 
the antibiotic course prior to enrollment in the study.  
7. Subjects positive for HIV, Hepatitis B or C.  Subjects with serologic evidence of 
Hepatitis B vaccination (HepB surface Ab without the presence of HepB surface Ag) will 
be allowed to participate. 
8. Subject currently has or has a known history of herpes zoster or cytomegalovirus (CMV) 
within [ADDRESS_1042069] has used any semi-permanent eyebrow coloring ( e.g., tinting, dying, etc.) within 
[ADDRESS_1042070] a poor candidate for the study.   
13. Subjects with absolute neutrophil count <1,000/mm3, or platelet count <50,000/ml. 
14. Subject used any of the following therapi[INVESTIGATOR_160764] 1: 
Systemic therapi[INVESTIGATOR_014]: 
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 21 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                      Disease Modifying Anti-Rheumatic Drugs (DMARDS), Biologics or 
immunosuppressants, such as: anakinra, adalimumab, azathioprine, 
glucocorticosteroids, cyclosporine, etanercept, infliximab, methotrexate, 
TNF inhibitors, ustekinumab, secukinumab, ixekizumab,  certolizumab 
pegol: 4 weeks or 5 half-lives whichever is longer 
 Oral retinoids: 12 weeks 
 Plaquenil: 8 weeks 
 JAK inhibitors (oral or topi[INVESTIGATOR_2855]): 1 year 
 Intralesional steroids on the eyebrow area: 4 weeks 
Topi[INVESTIGATOR_760922]: 
 Phototherapy, Laser Therapy: 12 weeks 
 Anthralin, bimatoprost, glucocorticosteroids, diphencyprone, 
diphenylcycloprophenone (DPCP), Squaric acid dibutyl ester (SADBE), 
minoxidil, pi[INVESTIGATOR_031], tacrolimus: 4 weeks 
 Topi[INVESTIGATOR_12969] (prescription and over-the-counter) that contain 
retinoids, retinol, alpha hydroxy acids (e.g. glycolic, lactic acids) and beta 
hydroxy acids (e.g. salicylic acid) on and around the eyebrow area: [ADDRESS_1042071] has participated in an investigational drug or device trial in which administration 
of an investigational study drug or device occurred within 30 days or 5 half-lives 
(whichever is longer) prior to Visit 1.  Subjects who have participated in a study of an 
investigational drug, device or biologic agent for alopecia areata (AA, AU or AT) within 
1 year of screening will be eligible to participate only with individual permission from 
the Medical Monitor. 
17. History of or current alcohol or drug abuse within 2 years of assessment for study 
enrollment. 
18. Screening ECG findings of: 
 QTcF >450msec for males or >470msec for females (use of the ECG algorithm is 
acceptable for this purpose) 
 Heart rate < 45 or > 100 beats/minutes (inclusive) 
 Rhythm disturbance other than sinus arrhythmia or ectopic supraventricular 
rhythm (ectopic atrial rhythm) 
 Conduction disturbance including PR >240msec, pre-excitation (delta wave and 
PR <120msec), second degree or higher AV block 
 Acute or chronic signs of ischemia  
 Left Bundle Branch Block 
 Prior myocardial infarction 
 
5.5. Concomitant Therapi[INVESTIGATOR_760929] 1 (Screening), the investigator or designee will question the subject to ensure they 
have not used any excluded therapi[INVESTIGATOR_014].  Concomitant therapi[INVESTIGATOR_760930] (Visit 1) until Day 197 (Visit 11).  Concomitant therapi[INVESTIGATOR_118186] (e.g. 
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 22 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                     prescription and over the counter [OTC]), and non-drug modalities (e.g., chiropractic, physical 
therapy).  
 
5.5.1. Permitted Concomitant Therapi[INVESTIGATOR_760931] a stable 
dose prior to study entry.  Vitamins, minerals, and dietary supplements are permitted while on 
study if the subject has been on a stable dose prior to study entry and, in the opi[INVESTIGATOR_684], will not affect the safety or efficacy of the subject during the study.   
Topi[INVESTIGATOR_760932], in the 
Investigator’s opi[INVESTIGATOR_1649], they will not affect the assessments of the subject during the study.   
Topi[INVESTIGATOR_760933]. Inhaled or intranasal corticosteroids are allowed in the study. 
 
Prior permitted concomitant medications taken within [ADDRESS_1042072]’s source document and eCRF.  In addition, any new 
permitted medications administered during protocol treatment and through Day 197 (Visit 11) will 
be documented in the subject’s source document and eCRF.   
 
5.5.2. Prohibited therapi[INVESTIGATOR_760934]-the-counter product known to affect hair growth is prohibited throughout 
the study period.  Any prescription topi[INVESTIGATOR_22775], over-the-counter topi[INVESTIGATOR_760935], alpha hydroxy acids (e.g. glycolic, lactic acids) and beta hydroxy acids (e.g. salicylic acid) 
or cosmetic procedures applied to or in close proximity around the eyebrow area that in the opi[INVESTIGATOR_760936].  New eyebrow tattooing, microblading, or pi[INVESTIGATOR_760937].  During 
this study, subjects are prohibited from using therapi[INVESTIGATOR_519736]. The 
investigator should notify the Medical Monitor, if any prohibited therapi[INVESTIGATOR_760938]. 
 
5.6. Subject Discontinuation from the Study 
Subjects will be informed that they are free to withdraw from the study at any time and for any 
reason.  The Investigator may remove a subject from the study if, in the Investigator’s opi[INVESTIGATOR_1649], it 
is not in the best interest of the subject to continue the study. Examples of other reasons subjects 
may be discontinued from the study are: a change in compliance with an inclusion or exclusion 
criterion, occurrence of AEs, occurrence of pregnancy, or use of a prohibited therapy. Notification 
of discontinuation will immediately (within 24 hours) be made to the Aclaris Therapeutics, Inc. 
study monitor.  
 
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 23 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                     In case of premature discontinuation of study participation, efforts will be made to perform all 
final study day assessments. The date the subject is withdrawn from the study and the reason for 
discontinuation will be recorded in the subject’s source documents and on his/her case report forms 
(eCRFs). All withdrawn subjects with ongoing AEs will be followed as specified in section 8.2.1 
of this protocol. 
 
The study may be discontinued at the discretion of Aclaris Therapeutics, Inc. Some examples of 
reasons for discontinuation are the occurrence of the following: 
 Increased frequency, severity or duration of known AEs 
 Medical, business, regulatory or ethical reasons affecting the continued 
performance of the study 
 Difficulties in the recruitment of subjects 
 
5.7. Subject Identifier (SI) 
The investigator or designee will assign a unique five-digit subject identifier (SI) to each subject 
at Visit 1.  
 
The SI format will be NN-NNN where the first 2 digits are the investigational center site number 
(using leading zeroes as appropriate). The final [ADDRESS_1042073] enrollment will continue until approximately 12 subjects meet all the entry criteria and 
apply study medication at Visit 2 (Baseline). Subjects who are enrolled and do not complete the 
study will not be replaced.  
 
6. INVESTIGATIONAL PLAN 
6.1. Study Design 
This is an open-label proof of concept study in subjects with unilateral or bilateral loss of some 
or all eyebrow hair due to AA, AU or AT. Subjects will treat affected eyebrow(s) with ATI-
[ZIP_CODE] Topi[INVESTIGATOR_28198] 0.46% twice-daily for [ADDRESS_1042074]-treatment 
follow up visit.  
 
  
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 24 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                     6.2. Study Flow Chart 
Visit Number [ADDRESS_1042075] identifier  X           5.7 
Inclusion/exclusion 
criteria X X          5.3/5.4 
Demographics & 
Medical History 
(including Alopecia 
History) X          
 7.3.1 
Brief physical 
examination  X          X 7.2.2 
Vital signs (Height 
and Weight at Visit 1 
only) X X X X X X X X  
X  
X X 7.2.[ADDRESS_1042076] Eyebrow 
Assessment  X X   X X X X X X X 7.1.2 
Local Tolerability 
Assessment 
(Investigator and 
Subject)  X 
Pre & 
Post 
Dose X X X X X X X X X 7.2.[ADDRESS_1042077] study 
medication 
application   X          6.6.6 
Study medication 
applications     6.6.6 
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 25 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                     Visit Number [ADDRESS_1042078] instructions  X X X X X X X X X X  6.4 
Concomitant 
therapi[INVESTIGATOR_014] X X X X X X X X X X X 5.5.1 
Adverse events   X X X X X X X X X X 8 
 
6.3. Study Visits Description and Procedures 
A written, signed informed consent form (ICF) must be obtained from each subject prior to 
performing any study related procedure ( i.e., physical examination, clinical laboratory sampling, 
urine pregnancy test, ECG, or photography). 
 
6.3.1. Visit 1/ Screening (Week -4 to 0)  
At this visit, the investigator or designee will: 
1. Review and explain the nature of the study to the subject, obtain the subject’s signature [CONTACT_760961] a signed and dated copy to the subject. 
2. Assign a SI to the subject. 
3. Confirm the subject meets all inclusion criteria and no exclusion criteria. 
4. Collect demographic and medical history information (including alopecia history). 
5. Collect concomitant therapi[INVESTIGATOR_519738]. 
6. Perform a brief physical examination. 
7. Measure vital signs (including Height & Weight at this visit only). 
8. Conduct an ECG. 
9. Send patient for clinical laboratory tests including serum pregnancy test (if subject is 
WOCBP). 
10. Identify the affected areas of eyebrow(s).  Affected area is defined as the area of the 
eyebrow hair loss identified at baseline. 
11. Perform a Clinician Eyebrow Assessment (CEA); a grade of [ADDRESS_1042079] 30% eyebrow loss for the subject to continue in the study. Note: the 
subject may have multiple patches of eyebrow hair loss, but at least one distinct patch must 
demonstrate a minimum hair loss of at least 30% (independent of any other patches).  
12. Have the subject complete a Subject Eyebrow Assessment (SEA); a grade of [ADDRESS_1042080] 30% eyebrow loss for the subject to continue in the 
study. Note: the subject may have multiple patches of eyebrow hair loss, but at least one 
distinct patch must demonstrate a minimum hair loss of at least 30% (independent of any 
other patches). 
13. Review the study instructions with the subject. 
14. Schedule Visit 2 as appropriate. 
 
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 26 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                     6.3.2. Visit 2/ Baseline (Day 1)  
This visit must occur within [ADDRESS_1042081] be defined as not clinically significant (NCS) by [CONTACT_093]. For WOCBP, the 
serum pregnancy test from Visit [ADDRESS_1042082] review the evaluator’s interpretation of each subject’s Visit 1 ECG prior to 
Baseline/Visit [ADDRESS_1042083] not continue in the study and apply study medication, if 
the Visit 1 ECG meets any of the Criteria in Exclusion Criterion 18). 
 
At this visit, the investigator or designee will perform the following procedures PRIOR TO 
APPLICATION OF STUDY MEDICATION: 
1. Subject should have clinical laboratory tests performed at the local laboratory on the same 
day as the visit. 
2.  Query the subject in a non-directive manner about any changes in her/his health since the 
previous visit and report changes on the appropriate form. 
3. Query the subject about any changes in her/his concomitant therapi[INVESTIGATOR_760939]. 
4. Confirm the subject meets all inclusion criteria and no exclusion criteria. 
5. Confirm the subject continues to comply with all study restrictions, is eligible to continue 
in the study and has followed all study instructions. 
6. Measure vital signs. 
7. Perform a urine pregnancy test for WOCBP; results must be negative for the subject to 
apply the first dose of study medication. 
8. The investigator or designee will perform a CEA; a CEA grade of [ADDRESS_1042084] 30% total unilateral eyebrow hair loss is required for the subject to apply the first 
dose of study medication.  Note: the subject may have multiple patches of eyebrow hair 
loss, but at least one distinct patch must demonstrate a minimum hair loss of at least 30% 
(independent of any other patches). 
9. Confirm subject is eligible to apply the first dose of study medication. 
10. Discharge from the study subjects who are not eligible to apply the first dose of study 
medication. 
 
For subjects who are eligible to apply the first dose of study medication the investigator or designee 
will perform the following procedures:  
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 27 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                     1. Have the subject complete a SEA; a SEA grade of [ADDRESS_1042085] 30% 
total unilateral eyebrow hair loss is required for the subject to apply the first dose of study 
medication.  Note: Subject may have multiple patches of eyebrow hair loss, but at least one 
distinct patch must demonstrate a minimum hair loss of at least 30% (independent of any 
other patches). 
2. Have the subject complete the SES question.  
3. Have the subject perform a pre-application Local Tolerability Assessment (LTA). 
4. The Investigator or designee will perform a pre-application LTA. 
5. Take standardized color photographs. 
6. Conduct an ECG. 
7. Dispense study medication to the subject. 
8. An investigational staff member will instruct the subject on the proper study medication 
application technique and will observe the subject’s first study medication application. 
9. A staff member will monitor the subject for at least [ADDRESS_1042086]-application LTA 10 (±4) minutes after the application 
completion time.  
11. The investigator or designee will perform a post-application LTA 20 (±4) minutes after the 
application completion time.  
12. Review the study instructions with the subject. 
13. Schedule Visit 3 as appropriate. 
 
6.3.3. Visits 3-9 (Weeks 1, 2, 4, 8, 12, 16 and 20)  
These visits must occur on the following weeks after Visit 2: 
 Visit 3, 1 week (±4 days) 
 Visit 4, 2 weeks (±4 days) 
 Visit 5, 4 weeks (±4 days) 
 Visit 6, 8 weeks (±4 days) 
 Visit 7, 12 weeks (±4 days) 
 Visit 8, 16 weeks (±4 days) 
 Visit 9, 20 weeks (±4 days) 
 
At these visits, the investigator or designee will perform the following procedures: 
1. Query the subject in a non-directive manner about any changes in her/his health since the 
previous visit and report all AEs on the appropriate form. 
2. Query the subject about any changes in her/his concomitant therapi[INVESTIGATOR_760939]. 
3. Confirm the subject continues to comply with all study restrictions, is eligible to continue 
in the study and has followed all study instructions. 
4. Measure vital signs. 
5. AT VISIT [ADDRESS_1042087] for clinical laboratory tests prior to the study visit (on 
the same day). 
6. Have the subject perform a LTA. 
7. The investigator or designee will perform a LTA. 
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 28 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                     8. AT VISITS 5-[ADDRESS_1042088] for WOCBP; results must be negative for 
the subject to continue in the study. 
11. AT VISIT [ADDRESS_1042089] complete the SES. 
12. AT VISITS 5-9 ONLY , take standardized photographs. 
13. Dispense and/or collect study medication as appropriate. 
14. Review the study instructions with the subject. 
15. Schedule the next visit as appropriate. 
 
6.3.4. Visit 10 (Week 24) 
This visit must occur 24 weeks (±4 days) after Visit 2. 
 
At this visit, the investigator or designee will perform the following procedures: 
1. Query the subject in a non-directive manner about any changes in her/his health since the 
previous visit and report all AEs on the appropriate form. 
2. Query the subject about any changes in her/his concomitant therapi[INVESTIGATOR_760939]. 
3. Confirm the subject continues to comply with all study restrictions and has followed all 
study instructions. 
4. Measure vital signs. 
5. Conduct an ECG. 
6. Confirm subject had clinical laboratory tests prior to the visit (on the same day).  
7. Perform a urine pregnancy test for WOCBP. 
8. Have the subject perform a LTA. 
9. The investigator or designee will perform a LTA. 
10. The investigator or designee will perform the CEA. 
11. Have the subject complete the SEA. 
12. Have the subject complete the SES.  
13. Collect all study medication. 
14. Take standardized photographs. 
15. Review the study instructions with the subject. 
16. Schedule the next visit as appropriate. 
 
6.3.5. Visit 11 (Week 28) 
This visit must occur 28 weeks (±4 days) after Visit 2. 
 
At this visit, the investigator or designee will perform the following procedures: 
1. Query the subject in a non-directive manner about any changes in her/his health since the 
previous visit and report all AEs on the appropriate form. 
2. Query the subject about any changes in her/his concomitant therapi[INVESTIGATOR_760939]. 
3. Confirm the subject continues to comply with all study restrictions and has followed all 
study instructions. 
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 29 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                     4. Conduct a brief physical examination. 
5. Measure vital signs. 
6. Conduct an ECG. 
7. Confirm subject had clinical laboratory tests prior to visit (same day). 
8. Perform a urine pregnancy test for WOCBP. 
9. Have the subject perform a LTA. 
10. The investigator or designee will perform a LTA. 
11. The investigator or designee will perform the CEA. 
12. Have the subject complete the SEA. 
13. Have the subject complete the SES.  
14. Take standardized photographs. 
15. Discharge the subject from the study. 
 
6.4. Subject Instructions 
An investigational center staff member will dispense and review the Subject Instruction Sheet to 
each subject at Visit 2 through Visit 10 (see Section 14, Appendix A). 
 
6.5. STUDY DURATION 
The duration of study participation is anticipated to be a maximum of [ADDRESS_1042090]. This 
includes the up to 28-day screening period, a 169-day treatment period and a 28 day no-treatment 
follow-up period. The final study visit (Visit 11) has a maximum allowable visit window of +[ADDRESS_1042091]’s last visit.  
  
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 30 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                     6.6. STUDY MEDICATIONS 
6.6.1. Study medication identity 
The study medication for this study is ATI-[ZIP_CODE] Topi[INVESTIGATOR_28198] 0.46%. The study medication 
is a clear, colorless to light pi[INVESTIGATOR_214225]. The inactive ingredients include: water, Transcutol P, 
propylene glycol, PEG400, dimethyl sulfoxide (DMSO), Kolliphor CS 20, benzyl alcohol, 
poloxamer 188, and povidone K30.  The study medications must be stored in a secure area with 
limited access under appropriately controlled and monitored storage conditions. 
 
Study Medication Information 
Study medication name [CONTACT_118261]-[ZIP_CODE] Topi[INVESTIGATOR_28198] 0.46% 
Manufacturer PMRS, Inc., Horsham, PA, [LOCATION_003] 
ATI-[ZIP_CODE] concentration (%) 0.46 
Pharmaceutical Form Topi[INVESTIGATOR_760940], 30 ml with screw cap 
Storage Conditions 59°F to 77°F (15°C to 25°C) protected from light, excessive heat, 
open flame and combustibles, out of direct sunlight and in a well-
ventilated, dry area  
Dose regimen  
Route Topi[INVESTIGATOR_760941]-daily application 
Duration of administration  24 weeks 
Other Supplies  Disposable applicators 
 
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 31 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                     6.6.2. Study medication packaging and labeling 
The study medication will be packaged in [ADDRESS_1042092] the following: 
 Protocol number 
 ATI-[ZIP_CODE] Topi[INVESTIGATOR_28198] 0.46% 
 Storage conditions 
 Sponsor information 
 Investigational drug warning 
 Space to enter Subject Identifier 
 
6.6.3. Method of treatment assignment 
This study is an open-label study and all subjects will receive ATI-[ZIP_CODE] Topi[INVESTIGATOR_28198] 0.46%. 
 
6.6.4. Subject Eligibility to Receive Study Medication 
At Visit [ADDRESS_1042093] is eligible to apply study 
medication. Eligibility requirements include, but are not limited to: 
 The subject must not apply the first dose of study medication unless all the required clinical 
laboratory test results are within the range of normal for the laboratory, or, if there are any 
abnormal results, they must be defined as not clinically significant (NCS) by [CONTACT_1275].  
 For WOCBP, the serum pregnancy test from Visit [ADDRESS_1042094] dose of study medication. 
 The subject must not apply study medication if the Visit 1 ECG meets any of the Criteria 
in Exclusion Criterion 18). 
 
6.6.5. Dispensing and collecting study medication 
The study medications must be dispensed only to study subjects, only at the investigational center 
noted on the FDA Form-[ADDRESS_1042095] the SI on each bottle label. 
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 32 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                      
At Visits 3-9, examine the subject’s dispensed study medication bottles, collect bottles that are 
empty or do not contain sufficient volume of study medication available for use with the applicator, 
and dispense additional bottles as appropriate following the instructions above. 
 
At Visit 10, collect all dispensed study medication bottles.  
 
Dispense a packet of study medication applicators to the subject each time a study medication 
bottle is dispensed. It is not necessary to collect unused applicators from the subject. 
 
The investigational center staff should make every effort to obtain all dispensed study medication 
from each subject. Two documented telephone contacts with the subject followed by a registered 
letter to the subject constitute adequate follow-up efforts. If these efforts fail, the reason for the 
failure must be noted on the appropriate study medication inventory eCRF and in the subject’s 
source documentation. 
 
6.6.6. Study medication application 
The study medications are for external, topi[INVESTIGATOR_760942].  
 
At Visit 2, the staff member will instruct the subject on the proper application technique as detailed 
in Section [ADDRESS_1042096]’s first study medication application. The staff member should 
record the time that the subject completes the first study medication application. Monitor the 
subject for adverse events for at least [ADDRESS_1042097]-baseline study visit (Visit 3 and higher), an investigational center staff member will document 
the study medication compliance in the eCRF. 
6.6.8. Dose modification 
Subjects should not modify the study medication application procedure or frequency without the 
investigator’s prior approval. All application modifications must be reported on the appropriate 
eCRF.  If any meaningful study medication intolerance or safety issue occurs, after consulting with 
the Aclaris Therapeutics, Inc. Medical Monitor (see page 1), the investigator or designee may 
direct the subject to modify the study medication application frequency. If the subject cannot 
perform the twice-daily application frequency to the affected eyebrow(s) for more than [ADDRESS_1042098] be removed from the study. 
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 33 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                     6.7. Study Medication Management 
6.7.1. Accountability 
The investigator or designee will maintain an accurate record of the receipt of the study medication 
as shipped by [CONTACT_118232], Inc. (or designee), including the date received and the 
condition of the study medications. One copy of this receipt will be returned to Aclaris 
Therapeutics, Inc. (or designee) when the contents of the study medication shipment have been 
verified and one copy maintained in the study file. In addition, an accurate study medication 
disposition record will be kept, specifying the amount dispensed for each subject and the date of 
dispensing. This inventory record will be available for inspection at any time. At the completion 
of the study, the original inventory record will be available for review by [CONTACT_118232], 
Inc. upon request. 
 
6.7.2. Return and disposition of study supplies 
At the completion of the study, all used and unused study medication bottles will be returned to 
Aclaris Therapeutics, Inc. (or designee) for disposal per Aclaris Therapeutics, Inc. (or designee’s) 
written instructions. 
 
6.8. Other Study Supplies 
Aclaris Therapeutics, Inc. will provide: 
 Supplies for urine pregnancy tests  
 Equipment, supplies and training for taking standardized photographs 
 Equipment, supplies and training for capturing ECGs for central reading 
 Disposable applicators 
 
6.9. Blinding  
6.9.1. Verification of blinding 
This study uses an open-label design.  
 
6.9.2. Unblinding the study medication 
This is an open-label study. 
 
7. STUDY ASSESSMENTS 
The investigator, a designated and appropriately trained staff member ( e.g., subinvestigator) or the 
subject will perform the study assessments according to the schedules noted below.  
 
The same individual should perform the assessments for a given subject throughout the study. If 
this becomes impossible, an appropriate designee with overlappi[INVESTIGATOR_760943].  
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 34 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                      
Similar lighting conditions and subject positioning should be used for all evaluations for a given 
subject. 
 
7.1. Effectiveness Evaluations 
The investigator will identify the affected area(s) at baseline in the source document and eCRF.  
The affected area is defined as the area of eyebrow hair loss identified at baseline.   
 
7.1.1. Clinician’s Eyebrow Assessment (CEA) 
The CEA is the investigator’s assessment of the affected area of the eyebrow(s) at a particular point 
in time. The investigator should NOT refer to any other assessments to assist with these assessments.  
 
At Visits 1, 2 and 5-11, the investigator or designee will assess the affected area of the eyebrow(s) 
using the scale below and report the one integer that best describes the amount of eyebrow hair 
present.  If both eyebrows are affected, each eyebrow should be evaluated separately: 
 
Clinician’s Eyebrow Assessment 
 
Grade Descriptor 
0 No eyebrow hair:  No terminal hairs are visible in the affected area(s)  
1 A little eyebrow hair:  Occasional terminal hairs are visible in the affected area(s) 
2 Some eyebrow hair:  Numerous terminal hairs are visible in the affected area(s)  
[ADDRESS_1042099] eyebrow hair: Mostly complete eyebrow regrowth with terminal hair in the 
affected area(s)  
4 Full eyebrow hair:  Complete eyebrow regrowth with terminal hair in the affected 
area(s) 
 
 
At Visit [ADDRESS_1042100] to continue in the study and to 
apply study medication to one or both eyebrow(s), he or she must have a CEA grade of [ADDRESS_1042101] 30% total hair loss in one or both eyebrows.  Note: the subject may have multiple 
patches of eyebrow hair loss, but at least one distinct patch must demonstrate a minimum hair loss 
of at least 30% (independent of any other patches). 
 
The investigator will record if vellus hair is present (Y/N) in the affected area at Visits 1, 2 and 5-
11. 
  
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 35 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                      
7.1.2. Subject’s Eyebrow Assessment (SEA) 
The SEA is the subject’s assessment of the affected area of the eyebrow(s) at a particular point in 
time. The subject should NOT refer to any other assessments to assist with these assessments.  
 
At Visits 1, [ADDRESS_1042102] will assess the affected area of the eyebrow(s) using the scale 
below and report the one integer that best describes the amount of eyebrow hair present.  If applicable, 
each eyebrow should be evaluated separately: 
 
Subject’s Eyebrow Assessment 
Grade Descriptor 
0 No eyebrow hair:   No thick, coarse hairs are visible  in the affected area(s) 
1 A little eyebrow hair:  A few thick, coarse hairs are visible  in the affected area(s) 
2 Some eyebrow hair:  Numerous  thick, coarse hairs are visible  in the affected area(s) 
[ADDRESS_1042103] eyebrow hair:  The majority of the affected area(s) of the eyebrow is covered 
in thick, coarse hairs  
4 Full eyebrow hair:   The affected area(s) of the eyebrow is fully covered in thick, 
coarse hair s 
 
 
An investigational staff member will identify the eyebrow to be evaluated to the subject, educate the 
subject on the SEA scale before each evaluation and direct the subject to assess the affected area of 
the eyebrow. The staff member should not influence the subject’s assessment. 
 
At Visit [ADDRESS_1042104] 30% total hair loss in one or both eyebrows.  Note: the subject 
may have multiple patches of eyebrow hair loss, but at least one distinct patch must demonstrate a 
minimum hair loss of at least 30% (independent of any other patches). 
 
The study staff member will report the SEA grade the subject indicates in the source document for 
each eyebrow. Both the subject and the study staff member must sign/initial the source document 
to indicate the subject performed the SEA as instructed. 
 
  
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 36 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                     7.1.3. Subject Eyebrow Satisf action (SES)  
The SES is the subject’s assessment of her/his satisfaction with the status of the affected eyebrow(s), 
relative to the amount of hair present, at a particular point in time. The subject should NOT refer to 
any other assessments to assist with these assessments.  
  
At Visits 2, 7, [ADDRESS_1042105] will assess the affected eyebrow(s) using the scale below and 
report the one integer that best describes her/his satisfaction with the status of the affected eyebrow(s).  
If both eyebrows are affected, each eyebrow should be evaluated separately: 
 
Subject’s Eyebrow Satisfaction 
Grade Descriptor 
[ADDRESS_1042106]’s assessment. 
 
The study staff member will report the SES grade the subject indicates for each eyebrow in the 
source document. Both the subject and the study staff member must sign/initial the source 
document to indicate the subject performed the SES as instructed. 
 
7.2. Safety Evaluations 
The safety in this study will be monitored on a frequent and regular basis and will be formally 
reviewed on a monthly basis by [CONTACT_30967], who are experienced in the treatment of 
alopecia, the Sponsor’s medical monitor, and the clinical director.  In addition to reporting adverse 
events throughout the study, the investigator, a designated and appropriately trained staff member 
or the subject, will perform study specific safety assessments according to the schedules noted 
below.   
 
An independent safety monitor will review the safety data monthly or more frequently, if needed. 
 
7.2.1. ECGs 
At Visits 1, 2, [ADDRESS_1042107] 12-lead ECG with a 10mm/mV amplitude, at 
25mm/sec and a 5-10-second duration. To ensure a steady heart rate the subject must rest quietly 
in the supi[INVESTIGATOR_21683] 5 minutes prior to performing the ECG.  
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 37 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                      
A central lab will provide equipment, supplies and site training.  In addition, the central lab will 
process the ECGs received by [CONTACT_118236] a secure study portal.  The ECG 
results will be interpreted by a qualified health professional (evaluator) and the interpretation 
reported either directly on the tracing or in a separate report.   The evaluator will interpret the 
results of every ECG and define the ECG as “normal” or “abnormal”.  Variations such as minor 
ST changes ( i.e., <0.5mm depression) and early re-polarization are considered normal.  
 
The investigator must review the evaluator’s interpretation of each subject’s Visit 1 ECG prior to 
Visit 2.  The investigator will review the evaluator’s interpretation of all ECG reports in a timely 
manner and comment on the clinical significance of any result that is defined by [CONTACT_760954].  
 
Any abnormalities that are, in the opi[INVESTIGATOR_871], CS must be reported as medical 
history if found prior to the start of the first study medication application or as an AE if found after 
the start of the first study medication application. 
 
7.2.2. Brief physical examination 
At Visits 1 and 11 the investigator or designee will perform a brief physical examination. The 
examination will include an assessment of the following: 
 General appearance 
 Vital signs (Section 7.2.3) 
 Head, eye, ear, nose and throat (HEENT) 
 Respi[INVESTIGATOR_696] 
 Cardiovascular 
 Abdominal 
 Extremities 
 Musculoskeletal 
 Lymphatic 
 Skin 
 Neurological 
 
Any measure that is, in the opi[INVESTIGATOR_871], abnormal AND CS must be recorded as 
medical history if found prior to the first study medication application or as an AE if found after 
the first study medication application begins.  
 
7.2.3. Vital signs 
At Visits 1-11 a qualified staff member will measure vital signs. The following items will be 
measured: 
 Body temperature 
 Pulse rate 
 Respi[INVESTIGATOR_760944]: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 38 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                      Blood pressure (systolic and diastolic) after the subject sits quietly for at least 5 minutes 
 Height (at Visit 1 only) 
 Weight (at Visit 1 only) 
Any measure that is, in the opi[INVESTIGATOR_871], abnormal AND CS must be recorded as 
medical history if found prior to the first study medication application or as an AE if found after 
the first study medication application begins.  
 
A systolic blood pressure >140mm Hg or a diastolic blood pressure >90mm Hg is considered 
abnormal and therefore must be defined as CS or not clinically significant (NCS) on the eCRFs.  
A weight >[ADDRESS_1042108] be defined as CS or NCS on the 
eCRFs.  
 
7.2.4. Clinical laboratory sampling 
Subjects will go to a local laboratory (to be determined) to have the clinical laboratory tests at 
Visits 1, 2, 7, [ADDRESS_1042109] for 
the entire study. The following tests, at a minimum, will be conducted: 
 
Chemistry Panel Complete Blood Count 
Albumin Hematocrit  
Alkaline phosphatase  Hemoglobin  
Alanine aminotransferase (ALT)  Platelet count  
Aspartate aminotransferase (AST)  Red blood cell morphology  
Blood urea nitrogen (BUN)  Red blood cell count  
Bicarbonate  White blood cell count  
Calcium White blood cell differential  
Chloride     % & absolute  
Creatinine     Basophils  
Glucose     Eosinophils  
Lactate dehydrogenase (LDH)      Lymphocytes  
Phosphorus      Monocytes  
Potassium      Neutrophils  
Sodium  
Total bilirubin  Complete Urinalysis  
Total protein   
Uric acid 
Total cholesterol, LDL, HDL 
Triglycerides 
 
Screening Tests Only 
Virology (HepB, HCV, HIV) 
Total Iron Binding Capacity (TIBC) 
Serum Iron  
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 39 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                     Serum Ferritin 
T3/T4, TSH 
Quantiferon  
Serum Pregnancy (Visit 1 only) 
 
The results of the clinical laboratory tests will be reported on the laboratory’s standard reports. 
The investigator must review all laboratory reports in a timely manner and note NCS or CS to 
define the clinical significance of any result that is outside the normal range for the laboratory. The 
investigator must date and initial every laboratory report.  
 
The investigator must review the Visit [ADDRESS_1042110] study medication application 
begins.  
 
7.2.5. Local Tolerability Assessment (LTA) 
The LTA is the investigator’s assessment of the average overall severity of signs and the subject’s 
assessment of the average overall severity of symptoms associated with irritation on each eyebrow 
considered separately. The investigator and subject must NOT refer to any other evaluation to assist 
with these assessments. This is not a comparison with the assessment at any other time point. 
 
At Visits 2-11, the investigator and the subject will evaluate the LTA signs and the LTA symptoms 
respectively.  
 
LTA Signs (assessed by [CONTACT_760955]): 
 Erythema 
 Edema 
 Scaling/dryness 
 
LTA symptoms (assessed by [CONTACT_760956]): 
 Stinging 
 Burning 
 
The investigator will assess the LTA signs as follows: 
 At Visit 2: 
o Prior to the first study medication application 
o 20 (±4) minutes after the application completion time. 
 At Visits 3-11 
 
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 40 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                     The subject will assess the LTA symptoms as follows: 
 At Visit 2: 
o Prior to the first study medication application report the LTA for each symptom 
over the previous 24 hours 
o 10 (±4) minutes after the application completion time report the average severity 
since the application completion time 
 At Visits 3-11: 
o Report the average LTA for each symptom over the previous [ADDRESS_1042111] describes the average overall 
severity on each eyebrow separately using the scales below: 
 
Local Tolerability Assessment – Erythema 
Grade Descriptor  
0 Clear: No erythema present  
1 Mild: Slight erythema  
2 Moderate: Definite erythema  
3 Severe: Marked, fiery erythema  
 
Local Tolerability Assessment – Edema 
Grade Descriptor  
0 Clear: No edema present  
1 Mild: Slight edema  
2 Moderate: Definite edema  
3 Severe: Marked  edema 
 
Local Tolerability Assessment – Dryness/Scaling 
Grade Descriptor  
0 Clear: No signs of dryness or scaling  
1 Mild: Slight roughness (may be more easily felt than seen), barely perceptible scaling  
2 Moderate: Moderate roughness, definite scaling  
3 Severe: Marked roughness, heavy scaling  
 
The subject, for the symptoms, should report the one integer that best describes the average overall 
severity on each eyebrow separately using the scales below: 
 
Local Tolerability Assessment – Stinging 
Grade Descriptor  
0 Clear: No stinging  
1 Mild: Slight tingling, not bothersome  
2 Moderate: Definite tingling, slightly botherso me 
3 Severe: Intense stinging, bothersome and/or uncomfortable  
 
  
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 41 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                      
Local Tolerability Assessment – Burning 
Grade Descriptor  
0 Clear: No burning  
1 Mild: Slight warmth, not bothersome  
2 Moderate: Definite warmth, slightly bothersome  
3 Severe: Intense feeling of heat, bothersome and/or uncomfortable  
 
Follow these steps to complete the LTA for each symptom by a subject: 
 An investigational center staff member, other than the evaluating investigator, will show 
the appropriate LTA symptom grading scale to the subject and instruct the subject on the 
time interval to be considered. 
 The staff member should not give any opi[INVESTIGATOR_760945]. 
 The subject should verbally indicate the appropriate grade for each eyebrow for each 
symptom and the staff member will report the grade in the source document. 
 Both the subject and the staff member must sign/initial the source document to indicate the 
subject performed the LTA for symptoms as instructed. 
 The staff member must not influence the subject’s assessment. 
 
7.2.6. Urine Pregnancy tests 
At Visits 2, and 5-11, a qualified staff member will perform a urine pregnancy test for subjects 
who are WOCBP. The urine pregnancy test kits used must have a minimum sensitivity of 25-mIU 
ß-HCG/milliliter (ml) of urine.  
 
Subjects who are WOCBP must have a negative serum pregnancy test result at Visit [ADDRESS_1042112]’s pregnancy documented and 
followed. 
 
7.3. Other Evaluations 
7.3.1. Demographics, medical history and alopecia areata history 
During Visit 1, the investigator or designee will interview each subject to obtain demographic 
information including date of birth, sex at birth, Fitzpatrick skin type, race and ethnicity.  
 
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 42 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                     The investigator or designee will interview each subject to obtain medical history information 
related to all medical conditions and disease states that, at Visit 1: are ongoing, require concomitant 
therapy or are, in the opi[INVESTIGATOR_871], relevant to the subject’s study participation.  The 
investigator or designee will also obtain an AA, AU or AT history at Visit 1.  In addition, the 
medical history of women who are not of childbearing potential should reflect the reason e.g. post-
menopausal for [ADDRESS_1042113]’s eyebrows.  
 
The photographs are to document the status of each subject’s eyebrows. The subject’s identity will 
not be revealed in the study photographs. 
 
At Visit 2, the photographs must be taken prior to the first study medication application. 
 
Equipment, supplies, training and detailed instructions for obtaining and managing the 
photographs will be provided to the investigational center prior to the initiation of subject 
enrollment. 
  
8. ADVERSE EVENTS 
Adverse events will be monitored throughout the study and immediately reported on the 
appropriate Aclaris Therapeutics, Inc. AE eCRF.   
 
8.1. Definitions 
8.1.1. Adverse events (AE) 
An AE is any untoward medical occurrence in a patient or clinical investigation subject 
administered a study medication and which does not necessarily have a causal relationship with 
the study medication. An AE can therefore be any unfavorable and unintended sign or symptom 
associated with the use of a study medication (including an abnormal laboratory finding), whether 
or not related to the study medication. Thus, any new, or clinically significant worsening of an 
existing sign, symptom or disease, should be considered an AE.  
 
Worsening of any of the eyebrow assessments should be reported as an AE ONLY if the use 
of the study medication is interrupted or discontinued or if therapy is required to manage 
the event.  
 
The investigator must, for any AE in a study medication treatment area, question the subject 
in detail to determine if there are any confounding factors ( e.g., irritation by [CONTACT_760957]) for 
any such AE.  
 
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 43 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                     Every new epi[INVESTIGATOR_457970] a chronic condition ( e.g., headaches, 
seasonal allergies, depression, and hypertension) should be reported as a separate AE, even if the 
condition is reported in the subject’s medical history. 
 
The investigator should, when certain, report a diagnosis rather than the signs, symptoms or 
clinically significant abnormal laboratory values associated with the AE. Otherwise, signs, 
symptoms or abnormal laboratory values may be used to describe the AE. 
 
Any CS abnormality discovered prior to the first study medication application should be reported 
as medical history, not as an AE. 
 
8.1.2. Serious adverse event (SAE) 
A Serious Adverse Event is any untoward medical occurrence that at any dose: 
 Results in death 
 Is life threatening 
 Requires inpatient hospi[INVESTIGATOR_1081] 
 Results in persistent or significant disability/incapacity, or 
 Is a congenital anomaly/birth defect 
 Is an important medical event 
 
The term “life threatening” refers to an event in which the subject was at risk of death at the time 
of event; it does not refer to an event that hypothetically might have caused death if it was more 
severe. 
 
Inpatient hospi[INVESTIGATOR_118196]-patient basis, even if released the same day. Prolongation of hospi[INVESTIGATOR_760946]. Hospi[INVESTIGATOR_272] a diagnostic test (even if related to an AE) 
or elective hospi[INVESTIGATOR_118198] (signing the ICF) are not 
themselves reasons for an event to be defined as a SAE. 
 
Important medical events are those that may not be immediately life threatening, result in death or 
hospi[INVESTIGATOR_059], but are clearly of major clinical significance and may jeopardize the subject or 
require intervention to prevent one of the outcomes listed in the SAE definition above. These 
should also usually be considered serious. Examples of such events are intensive treatment in an 
emergency room or at home for allergic bronchospasm, blood dyscrasia or convulsions that do not 
result in hospi[INVESTIGATOR_059]. 
 
8.1.3. Adverse event reporting period 
The investigator must start reporting non-serious AEs and SAEs starting with the subject’s first 
study medication application continuing until the end of the subject’s last study visit. 
 
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 44 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                     8.1.4. Severity 
The investigator must define the severity of each AE using the following definitions as a guideline. 
The investigator will consider the range of the possible severity of the event and identify the 
severity that is the most appropriate according to her/his medical judgment. 
 
Mild – Awareness of signs or symptom, but easily tolerated. 
Moderate  – Discomfort, enough to cause interference with usual activity. 
Severe – Incapacitating with inability to perform usual activity. 
8.1.5. Relationship to study medication 
The investigator will determine if there is a reasonable causal relationship between the study 
medication and an AE or not. The investigator will use her/his best medical judgment and consider 
all relevant factors (e.g., temporal relationship, location of the event, the subject’s relevant medical 
history, concomitant therapi[INVESTIGATOR_118199]) to determine the relationship of the AE 
to the study medication. The investigator will define the relationship of an AE to the study 
medication by [CONTACT_118238]: 
 
Related – There is a reasonable possibility that there is a causal relationship between the 
study medication and the AE. 
 
Not Related  – There is not a reasonable possibility that there is a causal relationship 
between the study medication and the AE. 
 
The term “reasonable causal relationship” means there are facts or arguments to suggest a causal 
relationship (International Conference on Harmonization (ICH) E2A). 
 
8.2. Reporting Procedures 
8.2.1. Procedures for reporting adverse events 
At each post randomization visit (Visit 2), the investigator or designee will question the subject to 
elicit AEs using a non-directive question such as “Has there been any change in your health since 
the previous study visit?”   
 
At Visit 2, the investigator or designee will monitor the subject for at least [ADDRESS_1042114]’s response to non-directed questioning regarding AEs, the 
investigator or designee will follow-up with directed questions and appropriate evaluations.  
Any AE noted during the reporting period must be reported in the source documents and on the 
appropriate AE eCRF.  
 
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 45 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                     AEs that are defined as “Not Related” to the study medications will be followed until they are 
resolved or until the subject’s last study visit. AEs that are defined as “Related” to the study 
medications will be followed until they are resolved or, if not resolved after the subject’s last study 
visit, until in the opi[INVESTIGATOR_871], the AE reaches a clinically stable outcome with or 
without sequelae. 
 
8.2.2. Procedure for reporting a serious adverse event 
Upon becoming aware of a SAE occurring during the AE reporting period, whether or not related 
to the study medication, the investigator must: 
 
1. Take the appropriate medical action to ensure the subject’s safety. 
2. Immediately inform the Safety Monitor of the SAE by [CONTACT_6968], ensuring that the subject 
information is deidentified (only subject initials and subject number) to:  
 ProPharma, Email: [EMAIL_2427]  
 Fax: ([PHONE_15881]  
3. Print a copy of the email confirmation from ProPharma and place in the study file. 
4. Within 24-hours complete, as fully as possible, an AE eCRF and an SAE form; e-mail the 
forms and any other relevant information ( e.g., concomitant medication eCRF, medical 
history eCRF, laboratory test results) to ProPharma (Aclaris Therapeutics, Inc. Safety 
Monitor). 
5. Monitor and document the progress of the SAE until it resolves or, if not resolved after the 
subject’s last study visit, until in the opi[INVESTIGATOR_118200] a clinically 
stable outcome with or without sequelae AND the investigator and Aclaris Therapeutics, Inc.  
Safety and Medical Monitor agree that the SAE is satisfactorily resolved. 
6. Inform the Aclaris Therapeutics, Inc. Safety Monitor of SAE updates, via telephone, 
followed by [CONTACT_118240] e-mail. 
7. Comply with the appropriate regulatory requirements and Aclaris Therapeutics, Inc. 
instructions regarding reporting of the SAE to the responsible Institutional Review Board 
(IRB) or Ethics Committee (EC). 
 
8.2.3. Safety Monitoring ECG Discontinuation Criteria 
Any subject who develops any of the following ECG criteria during the active treatment phase will 
be instructed to stop study medication and will be withdrawn from the study: 
 A post-study medication ECG result where the evaluator’s interpretation shows any of the 
following: 
 Clinically significant rhythm disturbance other than sinus rhythm or ectopic 
supraventricular rhythm (ectopic atrial rhythm) 
 Clinically significant conduction disturbance including PR >240msec, pre-
excitation (delta wave and PR <120msec), second degree or higher AV block  
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 46 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                      New finding of QRS>120ms (if not present at screen. For example, subjects with 
Right Bundle Branch Block at screening would not need to be withdrawn from the 
study if their subsequent ECGs remained unchanged) 
 Evidence of QT-interval prolongation, defined as an increase in the QT cF interval 
>60ms from Visit 1 
 New QTcF > 500 ms 
 Acute signs of ischemia or infarction 
 Any ECG abnormality which may, in the opi[INVESTIGATOR_871], represent a 
new medical issue of concern 
 
8.2.4. Study Medication Interruption and Discontinuation 
[IP_ADDRESS] Study Medication Interruption 
Treatment with ATI-[ZIP_CODE] Topi[INVESTIGATOR_118201]-[ZIP_CODE], or in the event of one or more of the 
abnormal laboratory values in Table 1. 
 
Table 1:  Study Medication Interruption Criteria 
Laboratory Test Interrupt Study Medication 
if: Resume Study Medication if: 
WBC count < 2 x 109/L ≥ 2.5 x 109/L 
ANC < 1 x 109/L ≥ 1.5 x 109/L 
Lymphocyte 
count < 0.5 x 109/L ≥ 0.75 x 109/L  
Platelet count < 75 x 109/L ≥ 100 x 109/L 
Hemoglobin < 8 g/dL or decrease > 2 g/dL ≥ 10 g/dL 
AST or ALT > [ADDRESS_1042115] < [ADDRESS_1042116] or within 20% of baseline values 
Serum creatinine >[ADDRESS_1042117] <1.[ADDRESS_1042118] or within 10% of baseline value 
 
If a subject has one or more of the abnormal laboratory values noted in Table 1, the investigator 
or designee upon receipt and review of the central laboratory report should instruct the subject to 
interrupt study medication applications. The investigator or designee should ask the subject about 
symptoms, concomitant illnesses and medications and repeat the test(s) as soon as possible.  The 
Medical Monitor must be notified of dose interruptions due to SAEs considered related to study 
medication or laboratory abnormalities noted in Table 1.  
If the retest confirms the abnormal laboratory value, then the study medication interruption should 
continue, followed by [CONTACT_166544] a week or sooner at the discretion of the investigator.  
The subject should be followed until the laboratory abnormality(s) return to normal or to baseline 
values.  Application of study medication may be resumed upon resolution of the abnormal 
laboratory values to the levels specified in Table 1 above.  
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 47 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                      
[IP_ADDRESS] Study Medication Discontinuation 
Study medication should be permanently discontinued in the event of any of the following: 
 Severe infection requiring parenteral antimicrobial therapy or hospi[INVESTIGATOR_059] 
 Symptomatic herpes zoster 
 Malignancy – except for non-melanoma skin cancer ( e.g., squamous or basal cell 
carcinoma) not in or near the treatment area 
 Anaphylactic or severe allergic reaction 
 WBC Count: < 1 x 109/L or second occurrence of < 2 x 109/L 
 ANC:< 0.5 x 109/L or second occurrence of < 1 x 109/L 
 Lymphocyte count:< 0.3 x 109/L or second occurrence of < 0.5 x 109/L  
 Platelet count: < 50 x 109/L or second event of < 75 x 109/L - in each case, value should be 
confirmed by [CONTACT_118241] 
 Hemoglobin: < 6.5 g/dL or second occurrence of < 8 g/dL - in each case, value should be 
confirmed by [CONTACT_118241] 
 AST or ALT: 
 > [ADDRESS_1042119] persisting for 1 week of study medication interruption or second event 
of > [ADDRESS_1042120] 
 > [ADDRESS_1042121] with total bilirubin >[ADDRESS_1042122] or symptoms of hepatocellular  
injury [fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, 
rash and/ or eosinophilia (>5%)]. 
 Serum creatinine: > [ADDRESS_1042123] persisting for >2 weeks of treatment discontinuation or 
second occurrence of > [ADDRESS_1042124] 
The continued treatment of subjects who experience other serious or severe adverse events 
considered related to study treatment should be discussed with the Sponsor’s medical monitor. 
 
9. PREGNANCY 
9.1. Definition of Women of Child Bearing Potential (WOCBP) 
WOCBP includes any female who has experienced menarche and who has not undergone 
successful surgical sterilization ( e.g., hysterectomy, bilateral tubal ligation, or bilateral 
oophorectomy) or is not postmenopausal. Postmenopausal is defined as ≥[ADDRESS_1042125] 
at Screening (Visit 1) and a negative UPT at Baseline (Visit 2) prior to randomization and monthly 
throughout the study. 
 
9.2. Highly Effective Methods of Birth Control 
The Investigator or subinvestigator will discuss the potential risk factors associated with pregnancy 
and the importance of maintaining a highly effective method of contraception throughout the study 
with all WOCBP (for example, those which result in a low failure rate - i.e., less than 1% per year- 
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 48 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                     when used consistently and correctly).  All WOCBP must use a highly effective method of birth 
control during the study and for 30 days after the final application of study medication in a manner 
such that risk of failure is minimized.   
 
Highly effective methods include: 
 Combined (estrogen and progestogen containing) hormonal contraception associated with 
inhibition of ovulation: 
o oral 
o intravaginal 
o transdermal 
 Progestogen-only hormonal contraception associated with inhibition of ovulation: 
o oral 
o injectable 
o implantable 
 intrauterine device (IUD) 
 Obstruction of fallopi[INVESTIGATOR_118202] (Essure™) 
 intrauterine hormone-releasing system (IUS) 
 vasectomized partner1 
 sexual abstinence2 
1Vasectomized partner is a highly effective birth control method provided that partner is the sole sexual partner 
of the WOCBP trial participant and that the vasectomized partner has received medical assessment of the surgical 
success.  
2 Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study treatments (study duration and [ADDRESS_1042126] study medication application). The reliability of sexual abstinence needs to be evaluated in relation to the 
duration of the clinical trial and the preferred and usual lifestyle of the subject. 
 
WOCBP must be on a highly effective method of birth control for the following timeframes prior 
to study entry:  
 Implants (on a stable dose for ≥90 days) 
 Injectables (on a stable dose for ≥90 days) 
 Patches (on a stable dose for ≥90 days) 
 Combined oral contraceptives (on a stable dose for ≥90 days) 
 Intrauterine devices (inserted for ≥30 days) 
 
Prior to trial enrollment, WOCBP must be advised of the importance of avoiding pregnancy during 
trial participation and of the potential risk factors associated with pregnancy while in study.  The 
subject must sign an informed consent form documenting this discussion.  During the trial, all 
WOCBP will be instructed to contact [CONTACT_118242] ( e.g., missed or late menstrual period). 
 
If a subject or investigator suspects that the subject may be pregnant prior to study medication 
administration, the study medication must be withheld until the results of a pregnancy test are 
available.  If pregnancy is confirmed, the subject must not receive study medication and must be 
discharged from the study.  
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 49 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                      
If, following study medication administration, it is determined that the subject may have been or 
was pregnant at the time of study medication exposure (including at least 2 days after study 
medication administration) the investigator must immediately notify the Aclaris Therapeutics, Inc. 
Medical Monitor and record the event on a pregnancy surveillance form. While not an AE or SAE, 
the investigator must report every pregnancy using a pregnancy surveillance form and follow the 
reporting procedures described for SAE reporting as described in Section 8.2.2. 
 
Protocol-required procedures for trial discontinuation and follow-up must be performed on the 
subject unless contraindicated by [CONTACT_8663] ( e.g., x-ray studies). Other appropriate pregnancy 
follow-up procedures should be considered if indicated. In addition, the investigator must report 
to Aclaris Therapeutics, Inc.’s Medical Monitor on the pregnancy surveillance form, follow-up 
information regarding the course of the pregnancy, including perinatal and neonatal outcome. 
Infants should be followed for a minimum of six weeks.  
 
If the outcome of the pregnancy meets the criteria for an SAE (i.e., ectopic pregnancy, spontaneous 
abortion, intrauterine fetal demise, neonatal death, or congenital anomaly [in a live born, a 
terminated fetus, an intrauterine fetal demise, or a neonatal death]), the investigator should follow 
the procedures for reporting SAEs. 
 
10. STATISTICAL ANALYSES 
10.1. Statistical Methods 
Summary descriptive statistics (N, mean, median, SD) by [CONTACT_760958].  Primary and secondary efficacy parameters are described below: 
 
Mean change from baseline in eyebrow growth will be calculated as the mean change in the 
Clinician’s Eyebrow Assessment (CEA) from Visit 2 (Baseline) compared to end of treatment 
(Visit 10). The CEA evaluates eyebrows on a scale from “No eyebrow hair” (grade 0) to “Full 
eyebrow hair” (grade 4).     
 
Mean change from baseline in the Subject’s Eyebrow Assessment (SEA) will be calculated from 
Visit 2 (Baseline) to end of treatment (Visit 10). 
 
Mean change from baseline in the Subject’s Eyebrow Satisfaction (SES) will be calculated from 
Visit 2 (Baseline) to end of treatment (Visit 10). 
 
All efficacy summaries will be based on the per-protocol population including all subjects who 
have Baseline (Visit 2) and Visit 10 efficacy data and no major protocol violations. 
 
Safety analyses will include descriptive statistics calculated on the safety parameters using the 
safety population. The proportion of subjects with treatment-emergent adverse events will be 
tabulated and presented by [CONTACT_10607] (MedDRA) System 
Organ Class. Vital signs and clinically significant abnormal laboratory results will also be 
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 50 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                     tabulated and presented. Change from baseline in the Local Tolerability Assessments (LTA) to 
end of treatment (Visit 10) will be summarized.  
 
Data from all enrolled and treated subjects will be presented and summarized. Safety summaries 
will include listings by [CONTACT_760959], and changes from pre-application values in vital signs. Adverse event 
summaries will be presented by [CONTACT_118218], both overall and by [CONTACT_7204].   
 
10.2. Sample Size 
This is the first US-based study with topi[INVESTIGATOR_760947]-[ZIP_CODE] Topi[INVESTIGATOR_760948], AU/AT.  No formal power calculations will be performed.  
 
11. TRAINING, MONITORING, DATA MANAGEMENT AND QUALITY 
ASSURANCE 
11.1. Training 
For each investigational center, there will be an initiation visit prior to enrolling any study subjects. 
 
It is strongly recommended that all investigators, other evaluators, study nurses, study coordinators 
or other applicable personnel attend this visit.  During this visit, participants will be trained to the 
protocol, study specific procedures, and the eCRFs.  Those unable to attend the initiation visit must 
receive on-site training from an appropriately trained individual prior to participating in any of the 
procedures and evaluations in this study.  
 
Clinical Research Associates (CRAs) and other applicable personnel will be trained prior to study 
initiation to familiarize CRAs with the disease, the Standard Operating Procedures (SOPs), the 
protocol and other study specific items.  Team organization, communication and operational issues 
will also be discussed. 
 
Aclaris Therapeutics, Inc. will provide an investigational center file to each center. 
 
11.2. Monitoring 
The conduct of the study will be closely monitored by [CONTACT_118246], Inc. 
to verify adherence to ICH Good Clinical Practice (GCP) guidelines and applicable SOPs.  Reports 
of these verifications will be archived with the study report.  The investigator will allow the Aclaris 
Therapeutics, Inc. representatives designee and/or and any regulatory agency to have direct access 
to all study records, eCRFs, corresponding subject medical records, study medication dispensing 
records and study medication storage area, and any other documents considered source 
documentation.  The investigator also agrees to assist the representative, if required. 
 
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 51 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                     11.3. Data Management 
Data management activities of this study will be subcontracted.  Edit checks and review processes 
will be performed by [CONTACT_17210]-contractor until all data clarifications are resolved. The data will be 
exported to be stored in SAS datasets (or equivalent) by [CONTACT_17210]-contractor. After all data 
clarifications are resolved and subject’s evaluability is determined, the database will be locked. 
 
11.4. Quality Assurance 
The study is conducted under the sponsorship of Aclaris Therapeutics, Inc. in compliance with the 
applicable regulatory requirements as well as applicable ICH guidelines, Declaration of Helsinki, 
and in respect of the Aclaris Therapeutics, Inc. and/or sub-contractor SOPs for study conduct and 
monitoring. 
 
Audits may be carried out by [CONTACT_118232], Inc. or Aclaris Therapeutics, Inc.’s 
representatives and inspections may be performed by [CONTACT_118247]/ECs before, 
during or after the study.  The investigator will provide the auditing/inspecting group direct access 
to all study records (e.g., eCRFs, subject medical records, study medication dispensing records) 
and the investigational center study facilities. The investigator and study staff will be available and 
will assist the auditing/inspecting groups as appropriate.  
 
12. ETHICS AND GENERAL STUDY CONDUCT CONSIDERATIONS 
12.1. Institutional Review Board (IRB)/Ethics Committee (EC) 
This protocol, informed consent form, any information provided to subjects, subject-recruiting 
advertisements, and any amendments to these items will receive IRB/EC approval prior to use. 
 
The IRB/EC must receive a copy of the Investigator’s Brochure, all protocol amendments, safety 
reports and other study related information as required by [CONTACT_214247]/EC procedures. 
 
12.2. Ethical Conduct of the Study 
The rights, safety and well-being of the subjects are the most important considerations in this study 
and take priority over the interests of society and science.  
 
This study will be conducted in accordance with the ethical principles originating from the 
Declaration of Helsinki, the ICH E6 GCP guideline, local regulatory requirements and, at US 
investigational sites, in compliance with HIPAA. The study will be conducted in compliance with 
the IRB/EC approved version of the protocol and any applicable amendments. 
 
This protocol, informed consent form, any information provided to subjects, subject-recruiting 
advertisements, and any amendments to these items will receive IRB/EC approval prior to use. 
Subjects will provide voluntary informed consent prior to initiation of any study related 
procedures. 
 
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 52 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                     12.3. Subject Information and Consent 
All subjects who participate in this study must be fully informed about the study in accordance 
with the GCPs, federal regulations, local regulations and, at US investigational sites, with HIPAA.  
The ICF will contain all the required elements in compliance with the current ICH E6 GCP 
guideline, local regulatory requirements. The investigator must have a defined process for 
obtaining voluntary informed consent from every subject.  
 
The ICF, approved by [CONTACT_2717]/EC, will be fully explained to the subject.  Prior to any study related 
procedures, including washout from therapi[INVESTIGATOR_014], the subject will voluntarily sign and date the ICF. 
The investigator must maintain each subject’s ICF in the investigational center’s study file and 
must provide each subject with a copy of the signed and dated ICF. 
 
12.4. Study Conduct and Protocol Amendments 
With the exception of eliminating an immediate hazard to a subject, the investigator should not 
deviate from the protocol or implement any changes without prior written approval from Aclaris 
Therapeutics, Inc. and prior review and documented approval from the IRB/EC. 
 
Changes that involve only logistical or administrative changes are allowed.  The investigator 
should document and explain any deviation from the protocol.  A protocol deviation is a non-
adherence to protocol-specific study procedures or schedules that does not increase the risk to a 
study subject and does not affect the scientific integrity of the study.   
 
A protocol violation is defined as any divergence from the protocol-specific study procedures or 
schedules that may result in an increased risk to a study subject or that affect the scientific integrity 
of the study.  All protocol violations must be reviewed by [CONTACT_118249], as directed by [CONTACT_1201]-specific procedures. 
 
12.5. Regulatory Documents 
The investigator must maintain a study file containing current and complete regulatory 
documentation in compliance with the current ICH E6 GCP guideline. This file will be reviewed 
as part of the routine monitoring for this study. 
 
12.6. Contractual Requirements 
A contractual agreement will be signed between Aclaris Therapeutics, Inc. and each investigator.  
This document will contain supplemental information, including financial terms, confidentiality, 
study schedule, third party responsibility, and publication rights. 
 
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 53 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                     12.7. Data Collection and Archiving 
12.7.1. Data collection  
The Investigator must maintain required records for all study subjects.  Data for this study will be 
recorded in the subject's source document and on the eCRFs.  All data on these eCRFs should be 
recorded completely and promptly.  A copy of the completed eCRFs for each subject will be 
retained by [CONTACT_118250]. 
 
Records of the subject’s participation in this study will be held confidential except as disclosure is 
required by [CONTACT_2371]. The study doctor, the sponsor, persons working on behalf of the sponsor, and 
under certain circumstances, the [LOCATION_002] Food and Drug Administration and the Institutional 
Review Board will be able to inspect and copy confidential study-related records that identify 
subjects by [CONTACT_2300]. Therefore, absolute subject confidentiality cannot be guaranteed. If the results 
of this study are published or presented at meetings, the subject’s identity will not be revealed. 
 
12.7.2. Source documentation 
Investigators must keep accurate separate records (other than the eCRFs) of all subjects' visits that 
include all pertinent study related information.  A statement should be made indicating that the 
subjects have been enrolled in this clinical study and have provided written informed consent.  Any 
AEs must be completely documented.  Source documentation includes results of any diagnostic 
tests conducted during the study.   
 
12.7.3. Archiving 
All pertinent data, samples, photographs, correspondence, original or amended protocol, reports 
and all other material relating to the study will be maintained securely in Aclaris Therapeutics, Inc. 
/contract research organization/investigator archives for the legally required duration for archiving. 
 
The investigator should maintain the essential study documents as specified in ICH GCP, and in 
compliance with all regulatory requirements. The investigator should ensure these documents are 
protected from accidental destruction or disposal. 
 
If the Investigator needs to re-assign responsibility for maintaining these documents (e.g., due to 
retirement) it must be transferred to a person willing to accept this responsibility.  The investigator 
must notify Aclaris Therapeutics, Inc., in writing, of the name [CONTACT_118262]. 
 
 
  
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 54 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                     13. References 
Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapi[INVESTIGATOR_2152] J. Alopecia areata update: Part II. 
Treatment. J Am Acad Dermatol . 2010;62(2):191-202. 
Arca E, Muşabak U, Akar A, Erbil AH, Taştan HB. Interferon-gamma in alopecia 
areata. Eur J Dermatol . 2004 Jan-Feb;14(1):33-6.  
ATI-[ZIP_CODE] Topi[INVESTIGATOR_760949]’s Brochure, August 2017. 
Barahmani N, Schabath MB, Duvic M; National Alopecia Areata Registry. History  
of atopy or autoimmunity increases risk of alopecia areata. J Am Acad Dermatol . 
[ADDRESS_1042127];61(4):581-91.  
Bilgiç Ö, Bilgiç A, Bahalı K, Bahali AG, Gürkan A, Yılmaz S. Psychiatric symptomatology and 
health-related quality of life in children and adolescents with alopecia areata. J Eu Acad 
Dermatol Venereol. 2014;28(11):1463-1468. 
Christiano, A.  2016.  Data on File.  
Craiglow BG, King BA. Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia 
Universalis in a Patient with Plaque Psoriasis. J Invest Dermatol. 2014;134(12):2988-2990. 
Craiglow BG, Liu LY, and King BA. Tofacitinib for the treatment of alopecia areata and variants in 
adolescents. J Am Acad Dermatol. 2017;76(1):29-32.  
Delamere FM, Sladden MJ, Dobbins HM, Leonardi-Bee J. Interventions for alopecia areata. 
Cochrane Database Syst Rev . 2008;16(2). 
Gilhar A, Kam Y, Assy B, Kalish RS. Alopecia areata induced in C3H/HeJ mice by 
[CONTACT_14234]-gamma: evidence for loss of immune privilege. J Invest Dermatol . 2005;124(1):288-9.  
Gupta AK. Efficacy of tofacitinib in treatment of alopecia universalis in two patients. J Eur Acad 
Dermatol Venereol . 2016;30(8):1373-1378. 
Hirota R, Tajima S, Yoneda Y, Okada M, Tashiro J, Ueda K, Kubota T, Yoshida R. 
Induction of hair regrowth in the alopecia site of IFN-gamma knockout mice by 
[CONTACT_118251]-gamma injection into the transplantation site. J Interferon  
Cytokine Res . 2003 Aug;23(8):433-9. 
Hordinsky MK. Current Treatments for Alopecia Areata. J Investig Dermatol Symp Proc . 
2015;17(2):44-46. 
Jabbari A, Dai Z, Xing L, et al. Reversal of Alopecia Areata Following Treatment With the JAK1/2 
Inhibitor Baricitinib. EBioMedicine . 2015;2(4):351-355. 
Jabbari A, Cerise JE, Chen JC, Mackay-Wiggan J, Duvic M, Price V, Hordinsky M, Norris D, 
Clynes R, Christiano AM. Molecular signatures define alopecia areata 
subtypes and transcriptional biomarkers. EBioMedicin e. 2016 May;7:240-7. 
Kim BY [CONTACT_118252]. Successful hair growth in a Korean patient with alopecia universalis 
following tofacitinib treatment. Singapore Med. J.,  2017 May; 58(5): 279-280. 
Kuwano Y, Fujimoto M, Watanabe R, Ishiura N, Nakashima H, Ohno Y, Yano S, 
Yazawa N, Okochi H, Tamaki K. Serum chemokine profiles in patients with alopecia  
areata. Br J Dermatol . 2007:157(3):466-73.  
Pi[INVESTIGATOR_77332] L, Guglielmelli P, Vannucchi AM. Ruxolitinib-induced reversal of alopecia universalis in a 
patient with essential thrombocythemia. Am J Hematol . 2015;90(1):82-83. 
Price VH. Treatment of Hair Loss. N Eng J Med . 1999;341(13):964-973. 
Price VH, Hordinsky MK, Olsen EA, et al. Subcutaneous efalizumab is not effective in the 
treatment of alopecia areata. J Am Acad Dermatol. 2008;58(3):395-402. 
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 55 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                     Ruiz-Doblado S, Carrizosa A, García-Hernández MJ. Alopecia areata: psychiatric comorbidity and 
adjustment to illness. Int J Dermatol. 2003;42(6):434-437. 
Safavi KH, Muller SA, Suman VJ, Moshell AN, Melton Iii LJ. Incidence of Alopecia Areata in 
Olmsted County, Minnesota, 1975 Through 1989. Mayo Clinic Proc . 1995;70(7):628-633. 
Scheinberg M, and Ferreira SB. Reversal of Alopecia Universalis by [CONTACT_118253]: A Case Report; 
Ann Intern Med .; 2016 Nov 15; 165(10): 750-751. doi: 10.7326/L16-0125. 
Strober BE, Siu K, Alexis AF, et al. Etanercept does not effectively treat moderate to severe 
alopecia areata: An open-label study. J Am Acad of Dermatol . 2005;52(6):1082-1084. 
Tosti A, Bellavista S, Iorizzo M. Alopecia areata: a long term follow-up study of 191 patients. J Am 
Acad Dermatol. 2006;55(3):438-441. 
Weise K, Kretzschmar L, John SM, Hamm H. Topi[INVESTIGATOR_118204]: 
Anamnestic and Clinical Criteria of Prognostic Significance. Dermatology. 1996;192(2):129-
133. 
Whiting, D.A., 2003. Histopathologic features of alopecia areata: a new look. Arch. 
Dermatol. 139, 1555–1559.  
Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by [CONTACT_28746] T lymphocytes and is 
reversed by [CONTACT_118254]. Nat Med. 2014;20(9):1043-1049. 
 
 
 
  
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 56 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                     14. APPENDIX A:  PARTICIPANT INSTRUCTION SHEET 
General Instructions: 
1. Before application of study medication, your face and eyebrow area should be clean (free 
of any makeup, moisturizers, sunscreen, etc.), and dry. This will allow the study 
medication to penetrate down into the skin to ensure you are getting the best application. 
2. The study doctor will instruct you to apply study medication to one or both eyebrows. 
You will apply the study medication to the entire eyebrow area, both with and without 
eyebrow hair.   
3. You will be asked to apply a thin layer of study medication to the affected eyebrow with 
an applicator as instructed by [CONTACT_118255]. Keep applying study 
medication to the affected eyebrow(s) throughout the study, even if hair is re-growing in 
these areas. 
4. You will want the tip of your applicator to be saturated but not too much as to cause 
drippi[INVESTIGATOR_007].  An applicator should only be dipped in the bottle once and then disposed of. 
5. Keep the study medication out of your eyes.  If the study medication gets in your eyes, 
rinse the area well with water for up to [ADDRESS_1042128] 6 hours. 
7. Remember to bring your study medication bottles, both used and unused, to each study 
visit. 
8. Avoid exposing your face to excessive natural or artificial ultraviolet radiation (e.g., 
sunlight, tanning beds) and use sunscreen on the face including the eyebrows, if 
excessive sun exposure cannot be avoided. 
9. Remove any products applied to the eyebrow area at least 1 hour before study visits.  Do 
not apply study medication less than 6 hours before a study visit.  If your visit is in the 
morning you should wait until after the visit to apply your study medication. 
10. Each bottle of study medication should be used for 14 days only, even if there is 
remaining study medication.  
 
Preparation for Study Medication Application 
1. Gather a clean, dry washcloth or towel, the study medication bottle, disposable 
applicators and a mirror. 
2. Wash your hands with soap and water before and after using this study medication. 
3. Gently wash your face, ensuring your eyebrow areas are clean. Use your normal 
cleansing regime as approved by [CONTACT_6814].  Do not use abrasive cleansers or 
materials on your face and eyebrow area.  
4. Pat your face dry with a clean towel and then let it air dry until it is completely dry to the 
touch. 
 
  
Protocol: ATI-[ZIP_CODE]-AAB-201 Aclaris Therapeutics, Inc. 
 
  
CONFIDENTIAL 
Page 57 of 57 
Version 1.0  
Date: 06FEB2018                                                                                                     Study Medication Application: 
1. Unscrew the cap from the bottle.  Place the open bottle on a stable, level surface.   
2. Dip a disposable applicator into the bottle of study medication for about [ADDRESS_1042129] your clean, dry washcloth over one eye. Swipe the 
applicator across your affected eyebrow ridge above the covered eye, applying a thin 
layer of study medication over the entire affected eyebrow area.  Your eyebrow area 
should be wet, but not drippi[INVESTIGATOR_118207].  Dispose of the applicator.  Do not dip the same 
applicator in the study medication bottle more than once. 
4. If you need additional study medication to cover your entire affected eyebrow, use a new 
applicator and repeat the application process as described in #2 and #3.  
5. If you are instructed by [CONTACT_118256], apply study medication 
to your other eyebrow following instructions in #2, #3, and #4. 
 
After Study Medication Application 
1. Securely close the study medication bottle and dispose of any used applicators.   
2. Wash your hands after using this product. 
3. Allow the study medication to completely dry for at least 10 minutes. 
4. Do not apply any products (moisturizers, sunscreens, cosmetics, etc.) to your eyebrow 
area until the study medication has completely dried, at least [ADDRESS_1042130] light. Do not refrigerate or freeze. Keep out of reach of children.  
 